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1. Introduction 
 
The blood-brain barrier (BBB) is the interface of peripheral circulation and central 
nervous system (CNS). It plays a crucial role in the supply of nutrients to the brain and in 
the exchange of information. The BBB is closely involved in many disease processes 
affecting the CNS. In addition, its control function in the passage of drugs to brain tissue 
is an important factor in the development of more specific and potent neuropharma-
ceutical agents. The following discourse introduces aspects of BBB biology, 
pharmacology and pathology, which are relevant to the research carried out for this 
thesis: First, an overview of drug delivery approaches is given. Second, the transcription 
factor NF-κB is described as a target for oligonucleotide-based anti-inflammatory drugs. 
Third, the vehicle for delivery of oligonucleotides used here, the cationic polymer 
polyethylenimine (PEI), is explained. Fourth, the neuroinflammatory disease Multiple 
Sclerosis (MS) is portrayed as one example of a disease with inflammatory damage to 
the BBB, which could be a therapeutic target for the drug delivery strategy developed in 
this project. 
 
1.1. Drug delivery strategies through the blood-brain barrier 
The presence of the BBB has major implications for the passage of compounds into the 
brain that are either hydrophilic or relatively large (> 400 - 600Da). Due to complex tight 
junctions, the paracellular transport across the cerebral endothelium, which forms the 
morphological substrate of the BBB, is limited. As a result, even the passive entry of 
certain low molecular weight nutrients (amino acids, glucose) is restricted. Several 
transport mechanisms have been characterized, including passive processes (diffusion), 
facilitative or carrier mediated transport, and active (energy requiring) processes. The 
diffusion of compounds across the endothelial cells of the BBB is dependent on several 
factors like lipid solubility, molecular weight, and electrical charge. There are three 
different classes of transport systems within the BBB: carrier-mediated transport 
systems, receptor-mediated systems, and active efflux transporters (Pardridge, 2002). 
Glucose and amino acids are transported into the brain by selective carrier mechanisms. 
For example, GLUT1 is a stereospecific facilitative carrier system, which transports 
glucose and other hexoses (galactose, mannose, 2-deoxyglucose, 3-O-methylglucose) 
with high affinity (Farrell and Pardridge, 1991). Nine distinct high affinity amino acid 
carrier systems have been described at the BBB for transport of small or large neutral 
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amino acids, of basic amino acids, and of acidic amino acids, respectively (Smith, 2000). 
Further carrier systems exist for the transport of amines (e.g., choline), nucleosides 
(e.g., adenosine), purine bases (e.g., adenine), monocarboxylic acids (e.g., pyruvate), 
and thyroid hormones (e.g., T3) (Smith, 1993). 
Receptor-mediated transport systems at the BBB include the transferrin receptor. Its 
expression at the BBB was first described by Jefferies et al. using a mouse anti rat IgG2a 
monoclonal antibody (OX26) (Jefferies et al., 1984). These receptors are responsible for 
transport of transferrin (and thus iron) into brain tissue. Several other receptors for 
peptides and proteins are present at the BBB, such as the insulin receptor (van Houten 
and Posner, 1979), leptin receptor (Bjorbaek et al., 1998; Golden et al., 1997), IGF-1 
and –2 receptors (insulin-like growth factors) (Frank et al., 1986), and LDL receptor (low 
density lipoprotein) (Meresse et al., 1989).  
The BBB also prevents entry of many substances, including potential 
neuropharmaceuticals, by active efflux systems. These mediate the ATP-dependent 
efflux of small molecules from brain to blood. The prototype of these efflux transporters 
is p-glycoprotein, which is the product of the multidrug resistance gene (MDR) that is 
known to have a broad substrate specificity (Borst, 1998). Immunoreactive p-
glycoprotein was first described at the brain microvasculature by Cordon-Cardo and 
colleagues (Cordon-Cardo et al., 1989). 
The development of non-invasive brain drug-targeting technologies for delivery of small 
and large drugs across the BBB is a pressing need. About 98% of all small-molecule 
drugs do not cross the BBB, and the uptake of large-molecule drugs through the BBB is 
completely hindered (Pardridge, 2002). Whereas small-molecule drugs provide 
symptomatic relief for brain disorders such as epilepsy and affective disorders, large-
molecule drugs possess the potential to cure many neurological disorders such as 
stroke, Alzheimer’s disease, ataxias, and brain tumors (Pardridge, 2002). The 
physiological transport systems at the BBB may be utilized for delivery of chemically 
very different neuropharmaceuticals. Carrier-mediated transport and active efflux 
systems are of importance for delivery of small-molecule drugs, while large-molecule 
drugs (peptide-based therapeutics, antisense drugs and genes) may be transported by 
receptor-mediated systems via endocytosis and transcytosis.  
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1.1.1. Small molecule drugs 
Two main factors determine, whether small molecules cross the BBB: the molecular 
weight (400 – 600Da) of a drug and its lipid solubility – the number of hydrogen bonds, 
which are formed by this molecule with water. For example, negligible transport would 
be expected, if the drug forms more than ten hydrogen bonds (Lipinski et al., 2001). 
Manipulations of small molecule drugs for drug delivery purposes will be performed 
mainly on hydrophilic compounds by blocking of hydrogen bond-forming functional 
groups (Pardridge and Mietus, 1979) or by increasing the number of methylene groups 
within a molecule (Diamond and Wright, 1969). Another way to increase transport 
properties of a drug is the so-called lipidization by chemical alteration of a molecule 
(Higuchi and Davis, 1970). One of these carriers is dihydropyridine (DHP) (Bodor and 
Simpkins, 1983). Further candidates are free fatty acid lipid carriers (Shashoua and 
Hesse, 1996) and adamantane (Tsuzuki et al., 1994). While the rate of influx of drug 
across the BBB may be improved, as apparent by a higher permeability-surface area 
product (PS), other pharmacokinetic properties, such as the area under the plasma 
concentration curve (AUC), may be adversely affected, i.e. decreased. Because the 
amount of drug delivered to brain is calculated as the product of [PSBBB] x [AUCplasma], 
the net effect of lipidization on brain delivery may be minimal (Pardridge, 1998).  
 
1.1.2. Carrier-mediated transport of drugs 
In order to use nutrient transport systems for drug delivery, the drug must have structural 
characteristics mimicking the nutrient normally transported by these carriers. 
Transporters bind their substrate molecule and change their conformation or temporarily 
open up a pore, allowing passage across the plasma membrane. L-DOPA is a pro-drug 
used for treatment of Parkinson’s disease. It utilizes the large neutral amino acid 
transporter (LNAA) at the BBB (Wade and Katzman, 1975). Inside the brain L-DOPA will 
be decarboxylated to dopamine – the active substance. Other examples of carrier-
mediated BBB transport of small molecules include the uptake of amino acid-based 
anticancer agents melphalan and acivicin by LNAA (Killian et al., 2000). Drugs exhibiting 
high affinity for the carrier can be specifically designed to enhance brain uptake. Takada 
et al. showed that the regional brain uptake of the amino acid derivative D, L – NAM 
exceeded that of the clinically used analogue, melphalan, by greater than 20-fold 
(Takada et al., 1992).  
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The characteristics of the active efflux pump p-glycoprotein explain experimental 
observations that some molecules with a MW > 400 - 600Da do not cross the BBB 
despite considerable lipophilicity. Drugs like cyclosporine, vinblastine and vincristine are 
subject to p-glycoprotein mediated efflux (Begley, 1996; Pardridge, 1998). 
 
1.1.3. Nanoparticles and Liposomes 
Solid or vesicular drug containers are being scrutinized for their potential in the delivery 
of both small molecules and macromolecules. 
Nanoparticles. Up to this time point the transport mechanisms of nanoparticles across 
the BBB are controversially discussed. Nanoparticles have sizes in the range of 100 – 
400nm, and therefore, they should not be able to pass the tightly sealed endothelial cell 
membrane. Further problems arise from the rapid clearance of systemically injected 
nanoparticles from the bloodstream, the opsonization by plasma proteins and the 
phagocytotic activity of the reticuloendothelial system (Gref et al., 1994; Schroeder et al., 
1998). In order to prevent the release of the drug from the nanoparticle, the transport 
system must be coated with stabilizers, such as polysorbate, poloxamers or 
poloxamines (Troster et al., 1990). Kreuter and colleagues reported the brain delivery of 
poly(butylcyanoacrylate) nanoparticles, which were sequentially coated with polysorbate 
80 and apolipoprotein B or E. The authors observed antinociceptive pharmacological 
effects when the nanoparticles were loaded with an opioid analog, the synthetic 
hexapeptide dalargin (Kreuter et al., 2002). The mechanism of entry into brain remained 
unknown. A receptor-mediated endocytosis by LDL receptors of these lipoprotein-
mimicking particles was proposed. However, it is known that polysorbate 80 (Tween 80) 
as a detergent causes the disruption of the BBB due to solvent destabilization of this 
barrier (Azmin et al., 1985). Therefore, opening of the BBB could also be the reason for 
a nanoparticle uptake observed by these authors. 
Liposomes exist as unilamellar vesicles with a diameter of 40 – 80nm or as 
multilamellar vesicles in a range from 0.3 - 2µm, which encapsulate the drug that has to 
be transported. However, classical liposomes do not show significant transport through 
the BBB because of their size and the rapid clearance from the circulation (Gref et al., 
1994; Sakamoto and Ido, 1993; Schackert et al., 1989). After conjugation of liposomes 
with polyethylene glycol (PEG) increased circulation times were observed 
(Papahadjopoulos et al., 1991). PEG on the liposome surface prevents the absorption to 
cells of the reticuloendothelial system (“stealth” liposomes) and increases the half life of 
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the circulating liposome in blood (Papahadjopoulos et al., 1991) Receptor-mediated 
endocytosis/transcytosis was observed by coupling these PEG-liposomes to a vector 
such as a monoclonal antibody directed against the transferrin receptor (Huwyler et al., 
1996) (see 1.2. below). 
 
1.1.4. Peptide-based neuropharmaceuticals 
Due to their hydrophilicity and size, peptides are generally excluded from passage 
through the BBB by simple diffusion. The methods under investigation for peptide and 
protein drug delivery may be divided in three principal strategies:  
a) Invasive procedures by either direct intraventricular administration of the drug or by 
temporary disruption of the BBB by injection of hyperosmolar solutions into the carotid 
artery. Approaches like intraventricular injection of a drug are used when the disease 
process is close to the brain surface, for example the delivery of glycopeptide and 
aminoglycoside antibiotics in meningitis (Nau et al., 1998). In addition to the invasive 
character of this method it must be considered that drug distribution within the brain is 
diffusion-limited (Jain, 1990), and due to the continuous turnover of the cerebrospinal 
fluid the clearance of the drug from the ventricle occurs rapidly.  
The temporary opening of the BBB by disruption of the tight junctions by infusion of 
hyperosmolar solutions like 2M mannitol into the carotid artery (Neuwelt and Rapoport, 
1984) is also an invasive procedure. There is evidence for chronic neuropathologic 
changes inside the brain (Salahuddin et al., 1988) because of entry of neurotoxic 
substances and plasma proteins (Nadal et al., 1995).  
b) Strategies that increase delivery of systemically injected drugs to brain by chemical 
manipulation (increased lipophilicity, see 1.1.1.), or inclusion of the compound into 
small liposomes (see 1.1.3.). 
c) Physiologic-based strategies, which exploit the various transport mechanisms at 
the BBB for nutrients, peptides, and plasma transport proteins (Bickel et al., 2001), 
which will be described in detail in section 1.2.  
 
1.1.5. Antisense drugs 
The principle of antisense oligodeoxynucleotides (ODN) is the selective inhibition of 
gene expression by binding to specific mRNA, thus preventing translation into a protein. 
Generally, ODNs are most effective inhibitors when they are targeted to the translation 
initiation site (Daaka and Wickstrom, 1990). Current research focuses on the mode of 
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action of antisense drugs, their specificity, stability, cellular uptake in cell culture as well 
as organ distribution and pharmacologic action in vivo. Unmodified phosphodiester 
ODNs (PO-ODN) with their strong negatively charged backbone have an excellent 
solubility in aqueous solutions and good hybridization characteristics. However, in vivo 
applications are limited due to the presence of 3’-exonucleases in serum leading to 
degradation of ODN (Sands et al., 1994; Shaw et al., 1991). Structural alterations of 
ODN, e.g. substituting the backbone oxygen by a sulfur atom (PS-ODN) improve the 
properties regarding exonuclease stability. The half-life of these phosphorothioates 
increases to > 18h in pure fetal calf serum (FCS) compared to 5min for PO-ODNs (Shaw 
et al., 1991). PS-ODN show enhanced cell uptake by binding to multiple cellular proteins 
in cell culture (Beltinger et al., 1995). The disadvantage of this binding behavior is an 
increased affinity to plasma proteins (albumin, α2-macroglobulin), which causes a loss of 
the bioavailability of the PS-ODN in the circulation (Soker et al., 1993). Moreover, 
neurotoxic properties of phosphorothioates were reported (Whitesell et al., 1993). In 
methylphosphonate ODNs (Me-ODN), the negatively charged oxygen of the 
phosphodiester bond is replaced by a neutral methyl group. They are also highly 
resistant against nucleases, and due to their lipophilic character are taken up by cells by 
passive diffusion or pinocytosis. Limitations in their application result from a lower water 
solubility and poor duplex formation due to their steric conformation. Therefore, to 
achieve the inhibition of a specific target sequence, 20-100-fold higher concentrations of 
Me-ODN compared to PS-ODN are needed (Maher and Dolnick, 1988). Peptide nucleic 
acids (PNA) are another example of very stable and neutral DNA analogues. PNAs 
retain high affinity for complementary RNA or DNA, but show poor cellular uptake 
without suitable delivery methods (Koppelhus and Nielsen, 2003).  
Due to size and/or charge, antisense drugs do not cross the BBB. Therefore, in vivo 
therapeutic effects in the CNS after systemic application of free drugs cannot be 
expected. While they are efficiently taken up by nervous tissue when applied directly into 
the cerebrospinal fluid (Schlingensiepen and Heilig, 1997), this invasive method is 
unsuitable for clinical applications. 
Efforts are made to create delivery vehicles for antisense drugs. A multitude of cationic 
lipid carriers are commercially available (e.g., lipofectin, DOTMA) and are used 
successfully in cell culture (Bennett et al., 1992; Schlingensiepen and Schlingensiepen, 
1997). However, non-specific carrier effects have to be excluded, as shown in a study 
with colon tumor cells (Yeoman et al., 1992). Immuno-liposomes and polymeric 
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nanoparticles were investigated regarding their delivery characteristics. Liposomes 
encapsulate ODNs and protect them very securely from extracellular nucleases. By 
linkage of liposomes to antibodies, targeting to specific tissues can be reached (Zelphati 
et al., 1993). Polymers such as lactose- or polyalkylcyanoacrylate polymers were used 
to protect ODNs from nuclease digestion (Chavany et al., 1992). Linear polyethylenimine 
(PEI) delivered antisense oligodeoxynucleotides into liver hepatocytes in vitro and in vivo 
(Chemin et al., 1998). These approaches are considered in detail below (1.2.). 
 
1.2. Receptor-mediated delivery of “chimeric peptides”  
1.2.1. “Chimeric peptide” strategies 
Chimeric peptides are synthetic constructs, which are designed to improve drug delivery 
through the BBB (Pardridge et al., 1987b). They are formed by chemical conjugation of a 
transport vector to a peptide or protein (potential neuropharmaceutic drug), which by 
itself would be unable to pass through the BBB. The vector represents a peptidomimetic 
MAb, which undergoes receptor-mediated endocytosis / transcytosis. Especially well-
characterized receptors at the BBB are the insulin and transferrin receptor, which under 
physiological conditions mediate transport of insulin and transferrin-bound iron.  
Because of its high expression, the transferrin receptor (TfR) is widely used for 
peptide / protein delivery across the BBB (see 1.2.2.). The “chimeric peptide” 
transport system binds to exofacial epitopes of the receptor, not competing with 
binding of the endogenous ligand (Pardridge, 2002). An efficient conjugation of 
vector and drug can be achieved by biotin-(strept)avidin technology that is known 
to retain the biological activity and good pharmacokinetic characteristics of these 
complexes (Pardridge, 1998). Figure 1 shows a BBB drug-targeting vector.  
 
Figure 1: Scheme of a chimeric peptide targeted to the TfR. Abbreviations: SA = streptavidin, B = 
biotin, -S- = thioether bridge, TfRMAb = transferrin receptor monoclonal antibody 
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Table 1 gives an overview of various applications of the anti rat MAb OX-26, anti mouse 
MAb 8D3, and anti human/primate MAb 83-14 as vectors for delivery of peptides, 
proteins, liposome coated drugs or genes. 
 
Vector/Species Drug/Category Target Reference 
OX-26/anti rat Methotrexate/Small MW drug TfR (Friden et al., 1991) 
OX-26/anti rat AZT/Small MW drug TfR (Tadayoni et al., 1993) 
OX-26/anti rat VIP/Peptide TfR (Bickel et al., 1993) 
(Wu and Pardridge, 1996) 
OX-26/anti rat NGF/Protein TfR (Kordower et al., 1994) 
(Backman et al., 1995) 
(Charles et al., 1996) 
(Backman et al., 1996) 
(Albeck et al., 1999) 
OX-26/anti rat DALDA/Peptide TfR (Bickel et al., 1994b) 
OX-26/anti rat BDNF/Protein TfR (Pardridge et al., 1994) 
(Pardridge et al., 1998) 
(Wu and Pardridge, 1999) 
(Zhang and Pardridge, 
2001a) 
(Zhang and Pardridge, 
2001b) 
OX-26/anti rat PO-ODN/Oligodeoxynucleo-tide TfR (Kang et al., 1995) 
OX-26/anti rat K7DA/Peptide TfR (Bickel et al., 1995) 
OX-26/anti rat PNA/Oligodeoxynucleotide TfR (Pardridge et al., 1995) 
OX-26/anti rat A beta 1-40/Peptide TfR (Saito et al., 1995) 
OX-26/anti rat PS-ODN/Oligodeoxynucleo- 
tide 
TfR (Wu et al., 1996) 
OX-26/anti rat Daunomycin/Liposome TfR (Huwyler et al., 1996) 
OX-26/anti rat GDNF/Protein TfR (Albeck et al., 1997) 
OX-26/anti rat EGF/Protein TfR (Deguchi et al., 1999) 
(Kurihara et al., 1999) 
OX-26/anti rat Gene/Liposome TfR (Shi and Pardridge, 2000) 
OX-26/anti rat BFGF/Protein TfR (Song et al., 2002) 
(Wu et al., 2002) 
OX-26/anti rat PLA/Nanoparticle TfR (Olivier et al., 2002) 
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8D3/anti mouse Gene/Liposome TfR (Shi et al., 2001) 
(Zhu et al., 2002) 
8D3/anti mouse A beta 1-40/Peptide TfR (Lee et al., 2002b) 
8D3/anti mouse PNA/Oligodeoxynucleotide TfR (Lee et al., 2002a) 
83-14/anti 
primate/human 
A beta 1-40/Peptide Insulin 
rec. 
(Wu et al., 1997) 
83-14/anti 
primate/human 
Gene/Liposome Insulin 
rec. 
(Zhang et al., 2002) 
   
Table 1: Recently used BBB vector-targeting systems 
 
1.2.2. The transferrin receptor system 
Transferrin (Tf) is a glycoprotein with a molecular weight of 80kDa (Laurel and Ingelman, 
1947), whose function is the transport of iron (Fe3+) in plasma and its delivery to cells. 
Iron is an essential component of many enzymatic functions and is a requirement for 
oxidative metabolism. At neutral pH, Tf uptake into cells is triggered by receptor 
mediated endocytosis (Baldwin et al., 1982). It has been observed that brain endothelial 
cells express more transferrin receptors (TfR) than other vascular beds of major organs 
(Jefferies et al., 1984) with exception of liver (Soda and Tavassoli, 1984), which is also 
the principal producer of plasma Tf. TfR were found on the surface of the luminal site of 
the brain capillary endothelial cell (Jefferies et al., 1984). TfR are disulfide-linked 
homodimers with a molecular weight of 190kDa, possessing an extracellular portion of 
88% (Jing and Trowbridge, 1990). After binding of the iron-Tf complex (holotransferrin) 
to this receptor, the complex is internalized into an acidic intracellular compartment 
(endocytosis), where the iron will be released and utilized or stored by the cell. Following 
release of iron, most of the empty binding protein (apotransferrin) can be recycled to the 
blood plasma, the rest is catabolized by the cell (Taylor and Morgan, 1990). A fraction of 
internalized holotransferrin will be transcytosed into the brain interstitium (Fishman et al., 
1987; Pardridge, 1988; Pardridge et al., 1987a). The mechanisms of endocytosis and 
transcytosis are controversial (Moos and Morgan, 2000). Alternative possibilities have 
been suggested for the process of transcytosis of iron: the transcytotic pathway via 
holotransferrin must avoid an iron release in the endosomal compartment of the 
endothelial cells, otherwise a different carrier protein would be required to deliver Fe3+ 
ions across the abluminal membrane (Raub and Newton, 1991). The free apotransferrin 
is thought to either undergo exocytosis across the endothelial plasma membrane back to 
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the blood, or to return to the circulation via the cerebrospinal fluid, or to be degraded 
within the brain tissue (Crowe and Morgan, 1992). 
Strong support for the transcytosis pathway derives from a number of brain uptake 
studies using the monoclonal antibody (OX-26, subtype IgG2a) (MAb) directed against 
the rat TfR, which was shown to bind preferentially to brain capillary endothelial cells 
after intravenous injection (Jefferies et al., 1984). These reports are summarized above 
(1.2.1.). Selective binding of OX-26 to the TfR at the BBB was shown by systemic 
injection of antibody. The antibody was also rapidly taken up by the liver, where it 
reached its saturation 1h after injection. In contrast, brain constantly extracted OX-26 
from the bloodstream over a time frame of 5h. Specific accumulation of antibody in 
heart, lung or kidney was not seen (Pardridge et al., 1991). Friden and colleagues 
(Friden et al., 1991) demonstrated a time-dependent transcytosis of radiolabeled OX-26 
using capillary-depletion experiments, which separate brain microvessels and brain 
parenchyma, and showed increase of uptake into brain compared to capillaries over 
time. Electron microscopy of an OX-26-colloidal gold conjugate revealed binding of 
conjugate to the luminal membrane of endothelial cells, accumulation in endocytotic 
vesicles (50-100nm), and release of gold particles to the extracellular space at the 
abluminal membrane of the endothelial cell (Bickel et al., 1994a). 
 
1.3. The transcription factor NF-κB and its regulation via inflammatory 
stimulation 
Transcription factors bind to the promoter region on the DNA to initiate gene 
transcription, supporting the function of RNA polymerases. NF-κB regulates the 
transcription of genes of a multitude of inflammatory mediators, like cytokines, 
chemokines, adhesion molecules, growth factors and other proteins that participate in 
the production of prostaglandins, leukotrienes and Nitric Oxide (NO) (Baeuerle and 
Baltimore, 1996; Baldwin, 1996), see Table 2. NF-κB family members are usually 
heterodimeric proteins – assembled from monomer subunits containing the 300-amino-
acid Rel domain at their N-terminus, which binds to specific recognition sequences on 
DNA, and to other Rel proteins (Rungeler et al., 1999). These specific DNA sequences 
are also called consensus sequences with the following structure: 5’-GGGACTTTCC-3’. 
This sequence motif has been found for the first time in the enhancer of the 
immunoglobulin light chain κ of B-lymphocytes (Max et al., 1981; Sen and Baltimore, 
1986). Up to this time point five NF-κB proteins have been identified in mammalian cells: 
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p65 (RelA), c-Rel, RelB, p50/p105 and p52/p100. p105 and p100 represent precursor 
molecules of which the smaller proteins p50 and p52 are separated off after proteolysis 
of the C-terminus (Beg and Baldwin, 1993; Lin and Ghosh, 1996). The most stable 
combination of known NF-κB proteins constitutes the p50/p65 heterodimer. NF-κB exists 
in the cytoplasm of most cells in its inactive form, where it is bound to inhibitory factors, 
like IκB (IκBα, IκBβ, IκBε), Bcl-3, p100 (IκBδ) and p105 (IκBγ) (intramolecular IκB) 
(Baldwin, 1996). The activation of NF-κB is regulated in the cytoplasm; cellular activation 
in response to a variety of inducers leads to the rapid release of NF-κB from IκB. 
 
 
Figure 2: NF-κB signal transduction pathway. Activation of nuclear factor kappa b (NF-κB) 
involves the phosphorylation-dependent ubiquitinylation of the inhibitor IκB and the subsequent 
degradation of IκB by proteasomes. The liberated NF-κB translocates to the nucleus, where it 
activates the transcription of various genes. 
 
Uncomplexed NF-κB rapidly translocates to the nucleus, and transcriptional activation of 
NF-κB regulated genes occurs within minutes after exposure to an inducing agent and 
can be considered as an important stress sensor. Cellular activation triggers an 
intracellular cascade of protein kinase activity – including protein kinase C, cAMP 
dependent protein kinase and casein kinase II (Baeuerle and Henkel, 1994) - which lead 
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to site-specific phosphorylation of two serines (Ser 32 and Ser 36) of IκBα, conjugation 
with ubiquitin, and proteasome-mediated degradation of IκB (Chen et al., 1996; Scherer 
et al., 1995) (Figure 2). Other isoforms of IκB have been identified, however, and the 
interaction of each IκB isoform with NF-κB may be regulated by different mechanisms 
(Baeuerle and Baltimore, 1996). 
 
Gene regulation by NF-κB also plays an important role in the central nervous system. 
Numerous extracellular and intracellular agents or events leading to an increase in gene 
expression in glial and neural cells have been described:  
• Neurotrophin (NGF) 
• Neurotransmitter (Glutamate) 
• Depolarization 
• Neurotoxid peptide (Aβ) 
• Developmental changes 
• Oxidative stress 
• Ceramide (C2-ceramide) 
• Cytokines (IL1, TNF) 
• Phorbolester (PMA) 
• Re-oxygenation 
• Lipopolysaccharide (Lipid A) 
adapted from (O'Neill and Kaltschmidt, 1997) 
 
 
Genes in/for  Examples 
Viruses Human Immunodeficiency Virus Typ 1 
(HIV-1) 
Simian Immunodeficiency  Virus (SIV) 
Simian Virus 40 (SV40) 
Adenovirus E3 Region 
Immunoreceptors Immunoglobulin k light chain 
Interleukin-2 receptor α chain 
T cell receptor ß2 
Major Histocompatibility Complex I 
(MHCI) 
Platelet activating Factor 
Tissue factors 
CD11b, CD48, CD69 
Cell adhesion molecules Endothelial leukocyte adhesion molecule 
1 (ELAM-1) 
Vascular cell adhesion molecule 1  
(VCAM-1) 
Intercellular cell adhesion molecule 1 
(ICAM-1) 
Cytokines and Growth factors β-Interferon 
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Tumor Necrosis Factor α (TNFα) 
Lymphotoxin (TNFβ) 
Interleukins (IL-1β, IL-2, IL-6, IL-8) 
Granulocyte/Macrophage colony stimula-
ting factor (GM-CSF) 
Granulocyte colony stimulating factor (G-
CSF) 
Makrophage colony stimulating factor (M-
CSF) 
Proenkephalin 
Acute phase proteins Angiotensinogen 
Serum Amyloid A precursor protein 
C reactive protein 
Lipopolysaccharide binding protein (LPS-
BP) 
Transcription factors and sub units c-rel 
NF-κB precursor p105 and p100 
IκBα 
p53 
c-myc 
Interferon regulating factor 1 
Enzymes/Proteins at oxidative stress NO synthase 
Cyclooxygenase-2 
12-Lipoxygenase 
Phospholipase A2 
 
Table 2: Target genes for NF-κB. Modified according to (Baeuerle and Baichwal, 1997) 
 
A pathophysiological role of NF-κB in neurological diseases, in which inflammatory 
reactions in the CNS are important, such as Multiple Sclerosis (MS) and Alzheimer’s 
disease, is likely. For example, the amyloid peptide Aβ, which is deposited in senile 
plaques in the brain of Alzheimer’s disease patients, was shown to activate NF-κB in 
neuronal cell culture and to be neurotoxic (Behl et al., 1994). On the other hand, a 
neuroprotective role of NF-κB activation in response to Aβ has been suggested 
(Kaltschmidt et al., 1997). When Tumor Necrosis Factor α (TNFα) or antisense 
treatment against IκB synthesis were used to induce NF-κB dependent gene expression, 
neurons exposed to Aβ showed an enhanced survival (Barger et al., 1995).  
Kaltschmidt and colleagues also investigated the immunoreactivity for the DNA-binding 
subunit p50 and for the DNA-binding and transactivating subunit p65 in an animal model 
of MS, Experimental Autoimmune Encephalomyelitis (EAE) (Kaltschmidt et al., 1994). 
Strong immunoreactivities for p50 and p65 were detected at the peak of clinical disease 
in microglial cells.  
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Important in the context of the present work is the fact that early activation of the NF-κB 
system is seen in endothelial cells of the BBB under inflammatory conditions (Laflamme 
and Rivest, 1999; Quan et al., 1997). Moreover, considerable evidence has accumulated 
showing that proinflammatory effects at the BBB are mediated via a NF-κB pathway in 
neuroinflammatory disease, such as Multiple Sclerosis (see 1.6.).  
 
Therefore, it should be possible to develop drugs with neuroprotective actions that are 
based on activation or repression of NF-κB. 
 
1.4. NF-κB decoys as pharmacological tools and potential drugs 
Transcription factor decoys are short double-stranded oligodeoxynucleotides (ODN), 
which contain so-called consensus binding sequences for a specific transcription factor – 
in this case NF-κB. Decoys corresponding to this “cis”- binding sequence (6-10bp) 
(Mann and Dzau, 2000) prevent the cis-trans interaction that occurs normally between 
transcription factors and the promoter region of their target genes (Figure 3).  
A correct regulation of gene expression is necessary for perfect development and 
function of the organism. The decoy approach is a variant in vivo gene therapy, as it 
strives to treat diseases by modulation of endogenous transcriptional regulation 
(Gambarotta et al., 1996; Schmedtje et al., 1997). 
There are a number of published reports of in vitro and in vivo work, in which the 
transcription factor decoy approach proved to be effective as a gene modulating method. 
The first in vitro studies were performed by inhibition of NF-κB dependent activation of 
the human immunodeficiency virus (HIV) enhancer in a transiently transfected B cell line 
and by inhibition of interleukin-2 (IL-2) secretion in Jurkat T leukemia cells (Bielinska et 
al., 1990). E2F decoys directed against transcription factors influencing genes 
responsible for cell cycle progression and cell growth are the most extensively 
investigated. They have been applied successfully as inhibitors of neointimal hyperplasia 
in coronary artery bypass grafts in several preclinical studies, followed by phase I/II 
human trials (Ehsan et al., 2001; Mann et al., 1999). Recently, an AP-1 (activator 
protein-1) decoy has been tested in vitro and in animals for the same indication (Ahn et 
al., 2002). 
 
                                                                                                                                            Introduction         15 
______________________________________________________________________________________ 
 
 
Figure 3: Transcription factor binds to the cis-element in the promoter region of its target gene ? 
gene activation, Binding of decoy ODN to the transcription factor prevents activation of target 
gene 
 
NF-κB directed decoys are able to manipulate a variety of genes, including those for 
cytokines, adhesion molecules, cAMP and protein kinase C activation, and Ig expression 
during inflammatory responses (Collins et al., 1995). Compared to the antisense 
approach, decoys may be advantageous because of their better ability to inhibit 
constitutively expressed factors by reducing their promoter activity, and to block multiple 
transcription factors binding to the same cis-element (Morishita et al., 1998). Moreover, 
investigation of endogenous gene regulation at the pre-transcriptional and transcriptional 
level can be studied by application of decoys (the antisense approach induces “loss of 
function” at the translational level) (Morishita et al., 1998). 
Limitations of this approach arise from the fact that a variety of transcription factors are 
responsible for the regulation of one gene, and on the other hand one transcription factor 
is involved in the regulation of a multiplicity of target genes. This wide-ranging effect may 
not be desired in all applications. Therefore, a well thought-out and careful selection of 
decoy sequences is an important concern. Equally critical are the problems of stability 
and targeted delivery (Dzau, 2002). Highly efficient cellular delivery to target cells and 
sparing of non-target cells are the two goals here. Just as in the case of antisense ODNs 
and gene delivery, development of non-invasive delivery strategies is required to 
eventually achieve clinical utility of the decoy strategy. A promising non-viral carrier 
system for DNA delivery is introduced in the next section. 
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1.5. Characterization of Polyethylenimine  
1.5.1. Role of PEI and its advantage over viral delivery strategies 
In recent years gene therapy using non-viral gene delivery systems, such as cationic 
lipids or cationic polymers, received increasing attention because of several advantages 
over viral gene delivery. Depending on the specific vector used, viral systems offer high 
transfection efficiency, and/or potential integration into the host genome. However, the 
problems of immunogenicity and pathogenicity are far from being solved, as recent 
incidents in clinical trials have demonstrated. (Somia and Verma, 2000; van der Eb et 
al., 1998). Most non-viral synthetic vectors are essentially based on the complexation by 
electrostatic interactions between negatively charged phosphate groups of the DNA and 
positively charged amino groups of the polymers, thus protecting the DNA from 
exposure to serum proteins, in particular from nuclease degradation. A major problem is 
the poor solubility of formed complexes with cationic carriers and deoxynucleotides and 
their tendency to aggregate in aqueous solutions. (Kircheis et al., 2001b; Vinogradov et 
al., 1998). Several approaches have been described to overcome these problems, e.g. 
the synthesis of graft copolymers with nonionic polymers like polyethylenglycol (PEG), 
which could form a water-soluble corona around complexes and keep them in solution 
(Kabanov et al., 1995).  
 
1.5.2. Structure and synthesis 
Among the various synthetic vectors, polyethylenimines (PEIs) have emerged as 
particularly promising due to high transfection efficacy in cell culture as well as in a 
variety of in vivo applications. PEI exists in two forms: linear and branched (Figure 4). 
Linear PEI results from cationic polymerization of 2-substituted 2-oxazoline monomer 
followed by a hydrolyzation to yield the linear product. In contrast, branched PEI is 
produced by cationic polymerization of aziridine monomers via a chain-growth 
mechanism and the reaction is terminated by an intramolecular macrocyclic ring 
formation (Godbey et al., 1999b).  
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Linear PEI     Branched PEI 
 
                
Figure 4: Structures of linear and branched PEIs 
 
PEI possesses a very high charge density potential – every third atom is an amino 
nitrogen, which can be protonated to an overall protonation of 20 - 45% (at pH values of 
7 and 5, respectively). At physiological pH only every fifth or sixth amino nitrogen is 
protonated (Suh, 1994). 
Besides their structure, polyethylenimines differ from each other by their molecular 
weight. A variety of PEIs are commercially available, e.g., 700Da, 2kDa, 22kDa (linear), 
25kDa, 50kDa, 70kDa, 800kDa. Efforts are being made to optimize the properties of PEI 
regarding transfection efficiency and cytotoxicity. 
 
1.5.3. DNA condensation and particle size 
PEI and DNA (plasmids / antisense deoxynucleotides) condense spontaneously by 
forming electrostatic ionic bonds as mentioned above. Atomic force scanning 
microscopy pictures of PEI-induced condensation of supercoiled plasmid DNA 5 - 7kb 
show that in presence of PEI (22kDa or 25kDa) the structure of saturated complexes is 
globular and often surrounded by folded loops of DNA (Dunlap et al., 1997). Size 
measurements performed by dynamic light scattering show particles of 90 - 130nm in 
diameter (25kDaPEI / plasmid) (Tang and Szoka, 1997). The surface charge of 
complexes can be determined by measuring of the ζ potential. Values of 30 - 35mV 
were reported at a nitrogen/phosphate (N/P) ratio > 4, which is usually required for 
complete complexation, compared to a potential of 37mV of PEI alone (Godbey et al., 
1999a; Ogris et al., 1999). The surface charges of PEI/DNA play a major role in the 
H3C-CH2-NH—[CH2-CH2-NH]n—CH2-CH2-NH3+
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association with the negatively charged lipids of the plasma membrane (Godbey et al., 
1999b). 
 
1.5.4. Cellular uptake and intracellular trafficking 
The uptake mechanism of positively charged polycation/DNA is mediated by nonspecific 
adsorptive endocytosis via electrostatic interactions with the cell membrane (Leonetti et 
al., 1990). The trafficking route of the complex from the endosome to the nucleus is not 
fully understood. This process could be the limiting step in efficient transfection. Due to 
the buffering ability of PEI protons will be bound and do not alter the pH in the 
endosomes, thus preventing a degradation of DNA by inhibition of degrading enzymes 
(Boussif et al., 1995). At the same time an influx of Cl- relieves this H+ gradient. As a 
result of increasing osmolarity, passive water uptake disrupts endosomal membranes 
and DNA reaches the cytoplasm (Godbey et al., 1999b). The transport of complex 
through the cytoplasm may involve diffusion in combination with trafficking along the 
cytoskeleton of the cell. The uptake into the nucleus itself seems to be mediated by 
formation of vesicles either from the nuclear envelope or the lysosomal membrane 
(Godbey et al., 1999b). Experiments injecting naked DNA or DNA in complex with PEI 
into the cytoplasm revealed that naked DNA could not reach the nucleus; complexes, on 
the other hand, were taken up by the nucleus (Pollard et al., 1998). Bieber and 
colleagues (Bieber et al., 2002) proved that transcription of a gene is possible, even if 
DNA remains integrated into its PEI complex. Therefore, effectiveness of DNA delivery 
does not depend on disintegration of DNA/PEI complexes. 
 
1.5.5. In vivo gene delivery 
While in vitro applications have shown very promising results, in vivo gene delivery has 
to overcome additional hurdles, such as anatomical size restrictions, interactions with 
biological fluids, binding to a variety of non-target cells, and extravasation into the 
targeted tissue (Kircheis et al., 2001b). Moreover, biological systems including the 
immune system of the body, the complement system and the reticuloendothelial system 
act as natural defense mechanisms to prevent attacks by foreign bodies. In vivo delivery 
is differentiated into local administration of drug (e.g., directly into tumors, or specific 
organs – brain, kidney, lung), and systemic application by injection of the drug into the 
blood stream. Intraventricular administrations of PEI/DNA complexes showing gene 
expression in brain were applied by several authors (Abdallah et al., 1996; Boussif et al., 
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1995; Goula et al., 1998; Lemkine et al., 1999). Systemic application to the lung for 
example, was investigated by Zou and colleagues, who found that a bolus injection of 
50µg DNA in 400µl glucose into the mouse tail vein led to transfection of alveolar cells, 
primarily because of vascular leakage around the lung alveoli (Zou et al., 2000). 
However, for in vivo applications, the amount of DNA and the bolus volume injected to 
prevent aggregation of PEI/DNA complexes must be reduced. 
Furthermore, there are also reports about application to the liver (Robaczewska et al., 
2001), kidney (Boletta et al., 1997) and subcutaneously growing tumor grafts (Kircheis et 
al., 2001a; Kircheis et al., 1999). 
 
1.5.6. Modifications of PEI 
To improve the properties of cationic polymers, especially for applications in in vivo gene 
transfer, modifications of PEI have been intensely investigated. With respect to two of at 
least four existing barriers for in vivo gene delivery (systemic circulation, biodistribution, 
endosomal escape, transfer to nucleus), different newly synthesized co-polymers have 
been suggested.  
The first barrier to systemic gene delivery is to maintain the integrity and stability of 
injected DNA in the circulation. Several groups used polyethylene glycol (PEG) to 
develop long-circulating polyplexes. This hydrophilic polymer shields polymer/DNA 
complexes. Strongly reduced plasma protein binding and erythrocyte aggregation of 
PEG-g (grafted)-800kDaPEI/DNA could be shown in comparison to non-modified PEI 
(Ogris et al., 1999). After systemic application of PEGylated complexes with PEI 25kDa 
or 800kDa Oupicky and colleagues observed a steric stabilization by increased 
resistance of complex to salt-induced aggregation. Moreover, they showed for the first 
time a prolonged half-life after shielding their complex with the multivalent N-(2-
hydroxypropyl)-methacrylamide (PHPMA). Half life in mice increased from < 5min to > 
90min after injection (Oupicky et al., 2002). To investigate the influence of the molecular 
weight of PEG, several PEGs (550Da to 20kDa) were combined with 25kDa PEI. Co-
polymers with 20kDa PEG yielded small, highly condensed particles of 51 ± 23nm, while 
using the 550Da PEG resulted in larger and diffuse structures of 130 ± 60nm. 550Da 
PEG did not prevent erythrocyte aggregation due to incomplete shielding of the positive 
charge of PEI. Cytotoxicity seemed to be independent of the molecular weight of PEGs. 
However, for in vitro gene expression studies 550Da PEG proved to be most efficient 
(Petersen et al., 2002). 
                                                                                                                                            Introduction         20 
______________________________________________________________________________________ 
The second hurdle is to efficiently deliver the gene complex to specific cells or tissues. 
Target specific application of molecules requires identification of cell surface receptors 
and the use of appropriate ligands for receptor-mediated endocytosis into tissue. 
Attachment of folic acid improved PEI-mediated transfection efficiency in the presence of 
serum, whereas the same effect could not be obtained with other anionic compounds 
such as cholic acid, citric acid, EDTA, or glutamic acid (Guo and Lee, 2001). Folate-
PEG-Folate-g-PEI was investigated regarding its transfection efficiency and cytotoxicity 
in colon adenocarcinoma cells and oral epidermoid cells. An optimal transfection and low 
cytotoxicity were achieved using a ratio of FPF/PEI = 5.2 : 1 at neutral polymer 
amine/DNA phosphate charge (Benns et al., 2002). The same group synthesized PEI 
derivatives with terminal galactose-g-PEG, which binds to asialoglycoprotein receptors in 
liver and could improve the transfection efficiency compared to the polyplex alone 
(Sagara and Kim, 2002). An epithelial growth factor (EGF)-PEG-g-PEI derivative was 
successfully applied was in human carcinoma cell lines. It is known that EGF receptors 
are overexpressed in a high percentage in different human cancer tissues (Blessing et 
al., 2001). 
 
1.5.7. LMW-PEI as preferred polymer  
Extensive use of different PEIs for in vitro and in vivo gene delivery is often limited due 
to high toxicity or unsatisfying transfection rates of the applied polymer (Chollet et al., 
2002; Fischer et al., 1999). Fischer et al. describe the synthesis of a low molecular 
weight polymer, LMW PEI, with favorable features, such as a low degree of branching, 
low cytotoxicity, small aggregate formation, high transfection efficiency, and insensitivity 
against serum compared to the commercially available high molecular weight 800kDa 
PEI (Fischer et al., 1999). Using size exclusion chromatography in combination with light 
scattering techniques and NMR-spectroscopy, they synthesized a polymer with a MW of 
2,700Da (referred to Dr. D. Fischer), which is less branched than the HMW PEI because 
of the increased number of secondary NH-groups. The formation of primary and tertiary 
NH-groups is responsible for branched polymers. In vitro cytotoxicity of LMW PEI was 
tested using the LDH release and the MTT-assay. No membrane damaging effect of 
LMW PEI was measured with ECV 304 endothelial cells or L929 fibroblasts by LDH 
assay after 30 or 60min. In contrast, HMW PEI (500µg/ml) released LDH into the 
medium after incubation for the same time. Electron microscopy showed HMW PEI 
polymer precipitates adhering to the cell surface in large clusters (2 - 6µm). The reaction 
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was followed by a necrosis of affected cells. On the other hand, LMW PEI aggregates in 
the range of 10-50nm could be detected on the plasma membrane, and endocytic 
vesicles of 350nm were visible inside the cell. In terms of transfection efficiency, the 
authors showed a 100fold increase of expression of luciferase using LMW PEI 
compared to HMW PEI at a N/P ratio = 26.67. This positive transfection behavior could 
be further improved up to a N/P ratio of 66.66. For HMW PEI transfection levels 
increased up to a N/P ratio of 13.33; higher ratios showed lower transfection due to 
cytopathic effects. Because of its favorable properties, the polymer used in this project 
was based on LMW PEI. 
 
1.6. Multiple Sclerosis – an inflammatory disease of the central nervous 
system 
1.6.1. Multiple Sclerosis as an autoimmune disorder 
The etiology of Multiple Sclerosis (MS) still has to be resolved, but it is known that it is a 
multifactorial disease. MS is very variable in onset and progression. Common symptoms 
include impaired vision due to an optic neuritis, paresis and paralysis, deficits in 
sensation, ataxia and fatigue (Al-Omaishi et al., 1999). There is strong evidence that 
autoaggressive T cells enter the CNS and attack the myelin sheaths surrounding 
neuronal cells (Hafler and Weiner, 1995). A second factor is a genetic disposition, which 
is seen in first grade relatives possessing an increased risk compared to the general 
population (Kantarci et al., 2002; Oksenberg and Hauser, 1997). Environmental 
circumstances are also being discussed (Rosati, 2001). 
The inflammatory reactions within the CNS affect the white matter, leading to multiple 
lesions associated with decreased conductive properties of the neurons. Periventricular 
brain areas are primarily affected. The brain tissue is characterized by perivascular 
mononuclear infiltrations and presence of myelin debris inside of macrophages (de Vries 
et al., 1997).  
 
1.6.2. Pathophysiological changes at the BBB under inflammatory 
conditions and MS 
An early step upon activation of brain microvasculature is the secretion of several 
mediators. Cytokines such as tumor necrosis factor α (TNFα), interleukin-1 (IL-1) and 
interleukin-6 (IL-6), which are present within the CNS, are of crucial importance for the 
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development of the inflammatory response. The secretion of cytokines leads to an 
alteration of properties of the BBB. They can increase its permeability, and trigger the 
release of mediators important for manifestation of an inflammation, such as 
eicosanoids, the derivatives of arachidonic acid. Arachidonic acid can be converted 
through the action of cyclooxygenase into prostaglandins (PGs) and thromboxane A2. 
One possible site of synthesis of these factors seems to be the endothelial cell itself (de 
Vries et al., 1995): after systemic administration of endotoxin or proinflammatory 
cytokines (e.g. TNFα) the expression of numerous pro-inflammatory proteins in brain 
endothelial cells is upregulated. These include the CD14 LPS receptor (Lacroix et al., 
1998), interleukin-1 (Quan et al., 1998b), TNF receptors p60 and p80 (Nadeau and 
Rivest, 1999; Osburg et al., 2002), cyclooxygenase-2 (Quan et al., 1998a), inducible 
nitric oxide synthase (iNOS) (Wong et al., 1996), and the adhesion molecules ICAM-1 
and VCAM-1 (Henninger et al., 1997). The promoter regions of these genes contain 
binding sites for the transcription factor NF-κB. 
BBB dysfunction is of paramount importance in MS. MRI scans unveil newly developing 
lesions by detection of BBB damage, complementing the standard clinical diagnostic 
criteria (McDonald et al., 2001). It had long been known from the EAE model that BBB 
damage precedes the onset of clinical symptoms (Claudio et al., 1989; Daniel et al., 
1983). 
Although the etiology of MS still remains elusive, studies in EAE revealed that a crucial 
event in the pathogenesis is a transmigration of activated T lymphocytes across the BBB 
(Wekerle et al. 1986; Hickey et al. 1991). Subsequent research into the role of adhesion 
molecule expression on BBB endothelium showed an increased expression of ICAM-1 
(Sobel et al. 1990) and VCAM-1 (Brosnan et al. 1995) in MS lesions compared to control 
brain tissue. Similar conditions were observed in EAE (Dopp et al. 1994; Steffen et al. 
1994). The latter studies also uncovered that expression of the adhesion molecules 
preceded clinical disease by several days. Dr. Engelhardt’s group delineated the 
interaction of α4-integrin (VLA-4) on encephalitogenic T lymphocytes and VCAM-1 on 
the BBB both in vitro and in vivo (Laschinger et al. 2000; Vajkoczy et al. 2001). 
Highlighting the importance of adhesion molecules on lymphocytes and endothelial cells 
in MS is the recent success in a clinical trial with an antibody to α4-integrin, natalizumab 
(Miller et al., 2003).  
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2. Objective of this work 
 
The aim of this project is to explore the potential of a novel vascular targeting strategy 
for future treatment of Multiple Sclerosis (MS). It is known that the blood-brain barrier 
(BBB) endothelial cells are intimately involved in early steps of pathogenesis of 
neuroinflammatory diseases. The inflammatory process starts with the transmigration of 
activated lymphocytes from the peripheral circulation into brain tissue (Hickey et al., 
1991; Wekerle et al., 1986) and leads to a functional breakdown of the BBB. During this 
process a number of vascular markers are being expressed, i.e. the adhesion molecules 
ICAM-1 and VCAM-1, which mediate the entry of autoaggressive T cells into the brain, 
and enzymes with pro-inflammatory effect (cyclooxygenase 2, COX-2, and inducible 
nitrous oxide synthase, iNOS). 
Hypothesis of this project: Upregulation of adhesion molecules and other pro-
inflammatory proteins in brain vascular endothelial cells can be inhibited by delivery of a 
NF-κB decoy ODN/PEI complex applying the transferrin receptor-mediated delivery 
strategy. 
Experimental aims: 
1. Chemical conjugation of the rat anti mouse transferrin monoclonal antibody 8D3 
to the ODN/PEI complex using the streptavidin-biotin linker technology 
2. Physico-chemical characterization of the delivery vehicle bioPEGPEI 
3. Measurement of cellular uptake and pharmacological effects of NF-κB decoy 
(vector system) in an in vitro model 
4. Determination of the pharmacokinetics of vector mediated delivery of ODN after 
systemic administration in vivo 
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2. Material and Methods 
2.1. Material 
2.1.1. Instruments 
 
β-radiation Counter LS6000SC      Beckman 
Centrifuge Rotina 48        Hettich 
DNA Sequencer ABI PRISM310   Perkin Elmer 
Electrophoresis apparatus: 
Power supply: Power PAC 1000     BIO-RAD 
Mini Sub Cell GT System 7x7cm     BIO-RAD 
Sub Cell GT System 15x15cm     BIO-RAD 
ELISA reader Spectrofluor Plus      Tecan 
Gel dryer Model 583        BIO-RAD 
Glass Teflon Homogenizer 1ml 
Handcounter Model 3        Ludlum 
Heating plate         Heidolph 
High speed Centrifuge Avanti J-25I      Beckman 
HPLC columns        TosoHaas 
HPLC LC module I plus       Waters 
Hybridization oven Shake’n’Stack      Hybaid 
Incubator Forma 
Scientific 
Intensifying Screen        Kodak 
Laminar flow         Nuaire 
Magnetic stirrer        Heidolph 
Microfuge 5415D        Eppendorf 
Phase contrast microscope TS100      Nikon 
pH meter 443i         Corning 
Phosphoimager        BIO-RAD 
Photometer UV/VIS 918       GBC 
Quartz cuvette 10mm        Fisher 
Rotor JA-10         Beckman 
Software analysis program (Molecular Analyst)    BIO-RAD 
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Submicron particle sizer Model 380/ZLS Nicomp Instr. 
Corp. 
Surgical lamp KL750        Schott 
Surgical microscope        Zeiss 
Thermo cycler GeneAmp PCR system2400   Perkin Elmer 
Tissue homogenizer Wheaton-Tenbroeck 94x20mm,  
Wall distance 0.25mm   neolab 
Transscreen Cassette BioMax, 20x25cm     Kodak 
UV illuminator FBTIV-816 Fisher 
Scientific 
Vacuum pump         Gast 
Vortexer Reax top        Heidolph 
Water bath 1083        GFL 
 
2.1.2. Chemicals 
 
Chemicals were purchased from Sigma, GIBCO Life Technologies, Mallinckrodt, Fisher 
Scientific, BioRad, Promega, and Pharmacia, if not otherwise mentioned. The degree of 
purity of all chemicals was “p.a.” (pro analysii). All radioactive chemicals were obtained 
from NEN/Perkin Elmer or Amersham Pharmacia. 
 
2.1.3. Enzymes 
 
T4 polynucleotide kinase        Promega 
catalyzes the transfer of the terminal [γ32P] phosphate of  
ATP to the 5’-terminus of polynucleotides or to mononucleotides  
bearing a 5’-phosphate group. 
Reaction buffer10x: 700mM Tris HCl (pH 7.6), 100mM MgCl2, 50mM DTT 
Conditions of incubation: 30min at 37°C.       
 
Klenow polymerase (5-10U/µl)      Promega 
DNA polymerase I Large (Klenow) Fragment Mini Kit 
The 5´→3´ polymerase activity of Klenow Fragment can be used  
to fill in 5´-protruding ends with unlabeled or labeled dNTPs. 
Reaction Buffer10X: 500mM Tris-HCl (pH 7.2 at 25°C), 100mM  
MgSO4, 1mM DTT. Incubation temperature: 1 hour at 37°C 
 
Super-Script II-Reverse Transcriptase (200U/µl)    GIBCO 
The enzyme catalyzes the synthesis of first strand cDNA. 
Buffer: 5x first strand buffer 
Reducing agent: DTT 0.1M 
                                                                                                         Material and Methods       
______________________________________________________________________________________ 
26
Taq DNA polymerase (5U/µl)      Promega 
Taq DNA Polymerase catalyzes the incorporation of dNTPs into  
DNA. It requires a DNA template, a primer terminus, and the  
divalent cation Mg++. Taq Polymerase contains a polymerization  
dependent 5'-3' exonuclease activity.  
Buffer: 10x PCR buffer 
 
T4 DNA Ligase (3 Weiss U/µl)      Promega 
T4 DNA Ligase (1-3U/µl) catalyzes the joining of two strands  
of DNA between the 5’-phosphate and the 3’-hydroxyl groups  
of adjacent nucleotides in either a cohesive-ended or blunt-ended  
configuration. 
Reaction buffer: 10x 300mM Tris-HCl (pH 7.8), 100mM MgCl2,  
100mM DTT, 10mM ATP 
Conditions of incubation: 16 hours at 4°C. 
 
Restriction enzyme 
Bst ZI (10U/µl)        Promega 
Isochizomers: Eag I, Ecl XI, Xma III, Eco 52I 
Restriction site: 5’...C↓GGCCG...3’ 
    3’...GCCGG↑C...5’ 
Incubation buffer: 6mM Tris HCl pH 7.9, 150mM NaCl, 
        6mM MgCl2, 1mM DTT 
        + Acetylated BSA (10mg/ml) 
Incubation temperature: 3 hours at 50°C 
 
 
2.1.4. Buffers and Solutions 
 
Synthesis of 8D3-SA 
8D3 in PBS 
Recombinant Streptavidin lyophilized from 20mM K2PO4 pH 6.5;  Sigma 
36mg dissolved in1mL water 
0.32M Sodium borate/1mM EDTA pH 8.0 
0.16M Sodium borate/1mM EDTA pH 8.0 
Traut’s reagent 1.38mg/mL 0.16M Sodium borate    Pierce 
Glycine 7.5mg/mL water 
0.02M PBS pH 7.0/1mM EDTA 
S-SMPB 4.58mg/mL Dimethylformamide (DMF)    Pierce 
Iodoacetamide 3.7mg/ml water      Pierce 
d-[8,9-3H(N)]-biotin        NEN 
Coomassie         Pierce 
 
i.v. pharmacokinetics  
RHB:     10mM HEPES 
  2.8mM CaCl2 
  1mM NaH2PO4 
  1mM MgSO4 
  141mM NaCl 
  4mM KCl 
                                                                                                         Material and Methods       
______________________________________________________________________________________ 
27
  10mM D-Glucose 
  pH 7.4 
 
Capillary depletion 
32% dextran in RHB 
 
Immunohistochemistry 
ABC-Elite (Vector Lab):   2 drops A per 5ml PBS + 2 drops B per 5ml PBS 
AEC stock solution:    1.6mg/ml in DMSO 
AEC working solution:  6ml AEC stock solution 
     50ml Sodium acetate 0.02M pH 5.1 
     4ml 3% H2O2  
 
Retardation assay 
Electrophoresis buffer:   TAE 50x stock solution 
     1M Tris base 
     1M Acetic acid 
     50mM EDTA 
     pH 8.5 
 
Stability tests 
Polyacrylamide gel electrophoresis 
Electrophoresis buffer:  TBE 10x 
     890mM Tris base 
     890mM Boric acid 
     20mM EDTA 
     pH 8.0 
 
Gel:     20% 15ml 
     10ml 37:1 Acrylamide/Bis acrylamide 
     3ml TBE 5x 
     1.85ml water 
     135µl 10% APS 
     10.5µl TEMED 
 
Extraction of nuclear fragments for NF-κB gel shift assay 
Buffer A:    10mM HEPES pH 7.9 
     1.5mM MgCl2 
     10mM KCl 
     1mM DTT 
 
Buffer C:    20mM HEPES pH 7.9 
     25% glycerol 
     0.42M NaCl 
     1.5mM MgCl2 
     1mM DTT 
 
Buffer A + 0.1% Triton X-100 
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NF-κB gel shift assay 
Binding buffer:    12mM HEPES pH 7.9   
4mM TrisHCl 
60mM KCl 
1mM EDTA 
1mM DTT  
 
Gel:  60ml 
  12ml TGE 5x  
  15ml 19:1 Acrylamide/Bis-acrylamide 
  30ml water 
  150µl 30% APS 
  72µl TEMED 
   
Electrophoresis buffer:  TGE 5x 
50mM Tris HCl 
380mM glycine 
2mM EDTA 
pH 8.5 
 
mRNA isolation 
2x binding buffer:   20mM Tris HCl pH 7.5 
     1M LiCl 
     2mM EDTA 
 
Lysis and binding buffer:  100mM Tris HCL pH 8.0 
     500mM LiCl 
     10mM EDTA pH 8.0 
     1% SDS 
     5mM DTT 
 
Washing buffer with SDS:  10mM Tris Hcl pH 8.0 
     0.15M LiCl 
     1mM EDTA 
     0.1% SDS 
  
Washing buffer:   10mM Tris HCl pH 8.0 
     0.15M LiCl 
     1mM EDTA 
 
Elution buffer:    10mM Tris pH 7.5 
 
Reconditioning solution:  0.1M NaOH 
 
Storage buffer:   250mM Tris HCl pH 8.0 
     20mM EDTA 
     0.1% Tween-20 
     0.02% Sodium azide 
 
                                                                                                         Material and Methods       
______________________________________________________________________________________ 
29
Northern blotting 
Formaldehyde gel electrophoresis 
Electrophoresis sample buffer 10x:  
  50% Glycerol (87%) 
  0.2M EDTA pH 8.2 
  0.25% Bromo phenol blue 
  0.25% Xylene cyanol 
 
Electrophoresis buffer:   MOPS 10x stock solution 
   0.2M MOPS 
     50mM Na-acetate 
     10mM EDTA pH 7.0 
 
Denaturating buffer:    10ml Formamide 
     3.5ml Formaldehyde 37% 
     2ml 5x MOPS 
 
Sample buffer:   50% Glycerine 87% 
     0.25% Bromo phenol blue 
 
Formaldehyde gel:   1% Agarose 
     85% purified water 
water and agarose are boiled in a microwave and 
cooled down to 60°C in a water bath 
     10% 10x MOPS 
     2.5M Formaldehyde 37% 
     0.05% Ethidium bromide (500µg/ml) 
 
Blotting 
SSC 20x:    3M NaCl 
     0.3M Na-citrate pH 7.2 
 
Pre and Hybridization 
Prehybridization buffer:  11.1M Formamide 
     30% 20x SSPE 
     0.5% SDS 
     14% purified water 
     1% denaturated salmon sperm DNA (10mg/ml) 
 
Hybridization buffer: prehybridization buffer with labeled probe 
 
SSPE 20x:    3M NaCl 
     200mM NaH2PO4 
     20mM EDTA pH 7.4 
 
Blot storage buffer:   0.5x SSPE, 1% SDS 
Stripping buffer:   0.05x SSPE, 0.3% SDS 
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For several purposes 
PBS:     20mM Sodium phosphate  
     150mM NaCl pH 7.4 
 
 
2.1.5. Media 
LB (Luria Bertani) media  10g Tryptone 
     5g Yeast extract 
     5g NaCl 
     pH 7.0 
 
fill up to 1L with purified water; autoclave for 30min at 121°C and 1atm 
for agar: 1L LB media and 15g Agar; autoclave for 30min at 121°C and 1atm 
Addition of Ampicillin 100µg/ml 
IPTG (Isopropyl-β-D-thiogalactoside) 0.1M, and X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactoside) were spread over the surface of a LB-Ampicillin plate, Absorption time 
30min at 37°C. 
 
SOB media    2g Tryptone 
0.5g Yeast extract 
1ml 1M NaCl 
0.25ml 1M KCl 
 
SOC media    SOB media and  
1M MgCl2.6H2O 
     1M MgSO4.7H2O 
 
Tryptone, Yeast extract, NaCl, and KCl are given to 97ml sterile water. The reaction mix 
is autoclaved and cooled down. 2M Mg2+ stock solution and 2M Glucose are added to a 
final concentration of 20mM. The media is filled up to 100ml and passed through a 
sterile 0.2µm filter unit. The media should have a pH of 7.0. 
 
8D3 cell culture 
DMEM +    10% FCS    PAA 
     1% Penicillin/Streptomycin 
     1% Non essential amino acids 
     1% Sodium pyruvate 
     2% L-Glutamine 
     0.4% β-Mercaptoethanol 
 
Stock solutions:    10000U/ml/10000µg/ml Penicillin/Streptomycin 
     100x Non essential amino acids 
     100mM Sodium pyruvate 
     200mM L-Glutamine 
     0.1% β-Mercaptoethanol in DMEM 
 
Washing buffer:   1x HBSS 
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     25mM HEPES 
     15% FCS 
 
Freezing medium:   30% FCS      
     10% DMSO      
     60% DMEM + 
 
Serum free medium: Ex-cell 610-HSF  JRH Biosciences 
2% L-Glutamine 
     1% Penicillin/Streptomycin 
     1% Sodium pyruvate 
     1% Non essential amino acids 
 
 
bEnd5 cell culture 
DMEM +:    10% FCS 
     1% Non essential amino acids 
     1% Penicillin/Streptomycin 
     1% Sodium pyruvate 
     2% L-Glutamine 
     0.4% β-Mercaptoethanol 
 
Stock solutions: 
     10000U/ml/10000µg/ml Penicillin/Streptomycin 
     100x Non essential amino acids 
     100mM Sodium pyruvate 
     200mM L-Glutamine 
     0.1% β-Mercaptoethanol in DMEM 
 
Washing buffer I:   25mM HEPES 
     10% FCS 
     90% DMEM + 
 
Washing buffer II:   1x HBSS 
     5mM EDTA 
     40mM HEPES 
 
Freezing media:   10% DMSO 
     50% FCS 
     40% DMEM + 
 
Trypan blue 0.4% 
Trypsin 0.25%/EDTA 1mM 
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2.1.6. Primers and Oligodeoxynucleotides 
 
Hybridization of transcription factor decoys 
The oligodeoxynucleotides were obtained from MWG Biotech in HPSF purified condition. 
 
NF-κB 1: 
5’ - CCT TGA AGG GAT TTC CCT CC – 3’ 
 
NF-κB 2: 
5’ – GGA GGG AAA TCC CTT CAA GG – 3’ 
 
Reverse Transcription 
Random Primer Hexamer –5’- pd (N)6 (500ng/µl)    Pharmacia 
50 A260 units 1unit = 26.5µg 
            50units = 1.325mg 
stock solution 1mg/ml 
working solution 500µg/ml 
 
PCR 
Primers for Northern blotting probes: 
 
Name  mRNA 
sequence 
Fragment size 
ICAM-1 Forward primer: 
GCTCAGGTATCCATCCATCC 
137 - 156 505 bp 
 Reverse primer: 
CTGAGATCCAGTTCTGTGCG 
642 - 623  
VCAM-1 Forward primer: 
TGAAATGCCTGTGAAGATGG 
12 - 31 268 bp 
 Reverse primer: 
CTCAAAACTGACAGGCTCCA 
279 - 260  
iNOS Forward primer: 
ATGTCCGAAGCAAACATCAC 
2291 - 2310 449 bp 
 Reverse primer: 
TAATGTCCAGGAAGTAGGTG 
2740 - 2721  
COX-2 Forward primer: 
GTGCCAATTGCTGTACAAGC 
1341 - 1360 540 bp 
 Reverse primer: 
TTACAGCTCAGTTGAACGCC 
1918 - 1894  
IκBα Forward primer: 
AGCAAATGGTGAAGGAGCTGC 
193 - 213 323 bp 
 Reverse primer: 
CCAGCTTTCAGAAGTGCCTCAG 
516 - 495  
IκBβ Forward primer: 
GCAGAATGACCTAGGCCAAACA 
349 - 371 328 bp 
 Reverse primer: 677 - 656  
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TAGCCTCCAGTCTTCATCACGC 
GAPDH Forward primer: 
ACCTCAACTACATGGTCTAC 
156 - 175 801 bp 
 Reverse primer: 
TTGTCATTGAGAGCAATGCC 
957 - 938  
 
 
2.1.7. DNA markers 
100 bp ladder 50µg         Promega 
 
2.1.8. Bacteria and Plasmids 
High efficient competent cells from E. coli JM 109    Promega 
Transformation efficiency: 1 x 108 cfu/µg DNA 
T/A cloning: pGEM -T- vector (50ng)     Promega 
 
2.1.9. Animals 
Male BALB/c mice 20-25g Charles River 
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2.2. Methods 
2.2.1. Characterization of the 8D3-SA vector complex 
2.2.1.1. 8D3 hybridoma culture 
8D3 hybridoma cells were grown under addition of mouse feeder cells (abdominal 
macrophages) and thymus lymphocytes in DMEM+ in T75 cell culture flasks. After two 
days cells were split into T175 flasks and fed until a total volume of about 1.2L was 
reached. The cells were centrifuged at 250g for 10min at 4°C and transferred into four 
850cm2 roller bottles containing serum free medium. Cells rotated for about one week at 
150rpm and 37°C/5% CO2 and were harvested by centrifugation at 6000g and 4°C for 
30min. Antibody supernatant was precipitated with ammonium sulfate (330g/L 
supernatant) at 4°C over night and centrifuged for 45min at 6000g at 4°C. The resulting 
pellet was resuspended in about 10ml PBS and dialyzed using a dialysis tubing with a 
molecular weight cut-off of 10,000Da (Sigma). The antibody was further purified by a 
HiTrap protein G column (Pharmacia), concentrated on Centriprep 30 columns 
(Millipore) and protein content was measured by BCA method (Pierce, Rockford, IL). 
The antibody was stored in aliquots at -80°C. 
 
2.2.1.2. Synthesis of 8D3-SA 
For thiolation the 8D3 antibody was mixed with Traut’s reagent (2-Iminothiolane) and 
incubated for 60min at RT on a magnetic stirrer. At the same time S-SMPB 
(Succinimidyl-4-(p-maleimidophenyl)butyrate) was added to streptavidin and reacted 
under the same conditions as the antibody. Glycine was added to quench both reactions 
for further 30min. The reaction mixtures were purified over a PD 10 column (Pharmacia) 
and protein peaks collected. 8D3 and streptavidin peaks were combined and incubated 
under gentle stirring on ice for two hours. The reaction was quenched with 10% 
iodoacetamide for 10 - 20min and 3H-biotin was added and the mixture transferred onto 
Superdex 200 HR 10/30 for purification. 1mL fractions were collected and 5µl aliquots 
were counted in a β-counter, and compared with peaks obtained in UV-detection. The 
8D3 : streptavidin = 1 : 1 fractions were pooled and a rechromatography was performed 
using the size exclusion column TSK 3000 SWXL. The samples were concentrated and 
the protein measured as mentioned above. 
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Reaction mechanisms: 
 
a) Thiolation of 8D3 with 2-Iminothiolane 
 
The imidoester group reacts with amines to form a stable, charged linkage, while leaving 
a sulfhydryl group available for further coupling. 
 
 
S
NH 2
+  Cl - - NH 2 + - N -  C - (CH 2)3 - SH
H   NH 2
+
8D38D3
 
 
 
b) Activation of Streptavidin with sulfo-SMPB (Succinimidyl-4-(p-   maleimido-
phenyl)butyrate) 
 
The reagent has an amine-reactive N-hydroxy-succinimide (NHS) ester on one end and 
a sulfhydryl-reactive maleimide group on the other end. It possesses a negatively 
charged sulfonate group that lends considerable hydrophilicity to the molecule. The NHS 
ester can react with primary amines in proteins to form stable amide bonds, while the 
maleimide end nearly exclusively reacts with sulfhydryl groups to create stable thioether 
linkages. 
 
N O C
O
O
C
 - NH 2 +
O
streptav idin
 - Nstr eptav idin
OH
N
O
O
N
O
O
 
 
 
 
c) Coupling of Streptavidin to the 8D3 monoclonal antibody 
 
Interaction between the sulfhydryl group of the antibody and the maleimide group of the 
activated streptavidin under formation  a stable thioether bond. 
 
 
NH 2
+  H
 - N Cstrep tav idi n
OH
S    (CH 2) 3    C      N  - 8D3
N
O
O
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2.2.1.3. i.v. pharmacokinetics of 3H-biotin-8D3-SA 
BALB/c mice were anesthetized with ketamine (100mg/kg) and xylazine (4mg/kg) 
intramuscularly and the right common carotid artery was retrogradely catheterized with 
PE10; 70µl of RHB pH 7.4/0.1%BSA containing 1.7µCi of 3H-biotin-8D3-SA (10.6µg) 
were injected into the jugular vein and arterial blood was withdrawn from the carotid 
artery at 0.25, 1, 2, 5, 10, 20, 30 and 60min after injection of the isotope solution. The 
blood samples were centrifuged (1500g, 10min) and plasma was counted for total 
radioactivity. Mouse brains were taken at 60min, solubilized in 1ml Scintigest and 
counted in a beta counter. Pharmacokinetic parameters were estimated by fitting plasma 
radioactivity data to a bi-exponential equation with a derivative-free nonlinear regression 
analysis (WinNonlin, BMDP-AR). The area under the plasma concentration curve (AUC) 
was calculated. The organ volume of distribution (Vd) of 
3
H-8D3-SA MAb was estimated 
from the ratio of radioactivity of the tissue (counts per minute per gram) and plasma 
concentration (cpm/ml). The brain permeability-surface area (PS) product was calculated 
as follows: 
     PS = (Vd – V0) . CP (60min)/AUC0 ? 60min  
where CP (60min) is the terminal plasma concentration and V0 is the plasma volume of 
the brain. The brain concentration (without intravascular content) was expressed as 
percentage of injected dose (ID)/g of brain, and was determined as follows: 
     %ID/g = PS . AUC0 ? 60min 
 
2.2.1.4 Capillary depletion 
The pharmacokinetic studies were performed as described under i.v. pharmacokinetics. 
After 60min the brain tissue was removed and homogenized in ice-cold physiological 
buffer (RHB) for capillary depletion analysis. The total brain homogenate was 
fractionated into the capillary pellet and the postcapillary supernatant by a dextran (16% 
final concentration, equal volumes of homogenate and 32% dextran) density 
centrifugation at 4,300g for 15min at 4°C in a swinging bucket rotor. 0.5ml aliquots of 
homogenate, postcapillary supernatant and the capillary pellet were digested in 
Scintigest and counted in a beta counter. Vd values for the different fractions were 
calculated as follows: 
     Vd = (cpm/g brain)/Cp(t) 
Where Cp(t) are the counts per minute per microliter of plasma at brain sampling time (t).  
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2.2.1.5. Cell culture of bEnd5 cells 
The cell line used in these experiments is a mouse brain endothelioma line bEnd5. Cells 
were rapidly thawed at 37°C and seeded into 6-well culture dishes in 2ml of medium. 
Typically, a cell count of about 1x106 cells/well was reached after day 6. The bEnd5 cells 
were grown in DMEM (high glucose) medium containing 10% fetal calf serum, 1% 
nonessential amino acids (10mM), 100 units/ml penicillin, 100 µg/ml streptomycin, 1% 
sodium pyruvate (100mM), 2% L-glutamine (200mM) and 0.4% ß-mercaptoethanol at 
37°C in a 5% CO2 atmosphere. Cells were fed all two days until confluence 
(approximately 6 days). 
 
2.2.1.6. Binding and internalization experiments 
For in vitro uptake studies the mouse brain endothelioma cell line bEnd5 was cultured in 
6-well dishes for 5 days at 37°C and 5% CO
2
to grow confluent. After washing the cells 
with ice-cold serum free DMEM the following tracer solutions were added:  
a) 50µl of 0.35µg 8D3-SA and 0.05µCi 3H-biotin diluted in DMEM/1%BSA to 2ml serum 
free DMEM+ 
b) 50µl of solution a) and additional 80µg (about 240fold excess) of uncoupled 8D3 
c) 50µl of solution a) and additional 80µg of the mouse anti-rat antibody OX 26 
The binding and uptake capacity was measured at 0, 15, 30 and 60min at 37°C 
solubilizing cells in 1N NaOH and counting in a beta counter. In order to remove the 
surface bound 
3
H-8D3SA and to calculate the internalization an acid wash step was 
performed by a 5-min-incubation of cells with HEPES/DMEM pH 3.0. The receptor 
binding was expressed in %bound/mg cell protein. 
 
2.2.1.7. Immunohistochemistry 
bEnd5 cells were grown in 96-well plates for 2 days and fixed with 3% PFA for 3min. 
Endogenous peroxidase and unspecific staining were blocked with 0.3% H2O2 (5min) 
and 3% BSA (30min), respectively. The cells were incubated either with 10µg/ml 8D3 or 
8D3-SA. As a secondary antibody a biotinylated rabbit anti mouse antibody (5mg/ml, 
Vector Lab) was used. Visualization was performed with the avidin-biotin-peroxidase 
method (Vector Lab), using aminoethylcarbazol (AEC) as a substrate (20 - 30min at 
37°C). 
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2.2.2. Physico-chemical properties of bioPEGPEI/ODN or 8D3SA-
bioPEGPEI/ODN 
 
2.2.2.1. Hybridization of transcription factor decoys 
The complementary single stranded oligodeoxynucleotides (transcription factor decoys), 
were dissolved at a concentration of 1µg/µl in water, and were hybridized in a thermo 
cycler under the following incubation conditions: 5min at 95°C, 1h at 60°C, 1h at 35°C 
and 30min at RT. The annealed double strands were stored at -20°C. 
 
2.2.2.2. HABA (2(4'-hydroxyazobenzene) benzoic acid) assay 
The incorporation of biotin into the PEGPEI copolymer at the tip of the PEG3400 was 
determined with the streptavidin-HABA assay. A 0.7ml mixture of HABA (0.005M) in 
0.01M NaOH and streptavidin (0.05mg/ml) in 0.05M Na2HPO4 / 0.15M NaCl pH = 6.0 
was added to a spectrophotometer microcuvette. The absorbance at 500nm was 
measured and 2µl - 5µl increments were successively added of either 0.167mM biotin 
standard in 0.05M PBS pH 6.0, buffer control PBS pH 7.4, 0.147mM bioPEG3400, or 
0.355mM bioPEG3400PEI. The decrease in absorbance at 500nm caused by biotin 
displacement of HABA from streptavidin was recorded with each successive addition of 
4 - 6 aliquots of either biotin standard or experimental sample. The results were 
analyzed by linear regression analysis (∆ A500 vs. µl sample or buffer volume). 
 
2.2.2.3. Complex formation 
4µg of double stranded NF-κB decoys (1µg/µl) and the appropriate amounts of 
bioPEGPEI (MW 6,400 Da) (0.1µg/µl) were added to 20mM PBS pH 7.4 to yield a total 
volume of 50µl. The mixture was pipetted thoroughly and incubated for 10min at RT for 
complex formation. 
 
2.2.2.4. Polyacrylamide gel electrophoresis (PAGE) 
Free single and double stranded ODNs were compared with bioPEGPEIODN complexes 
incubated in 10mM PBS pH 7.4 and DMEM+ with 20% rat serum at 37°C for 0min, 
30min or 2h. The stability of N/P ratios from 3:1 to 10:1 was investigated on a native 
20% PAGE 16 x 20cm with cooling function. DNA was stained after electrophoresis with 
SYBR GOLD (Molecular Probes). 
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2.2.2.5. Retardation assay 
The 50µl complex mixture was loaded onto a 15 x 15cm 1% agarose gel stained with 
ethidium bromide. Electrophoresis was carried out at 140V for 2h in 1x TAE running 
buffer. The gel was visualized and photographed under UV-detection. 
 
2.2.2.6. Binding characteristics of 8D3-SA to its ligand bioPEGPEI/NF-κB 
Another approach to verify the binding behavior of the vector 8D3-SA to its ligand 
bioPEGPEI/NF-κB can be performed by incubation of both components followed by 
separation on an agarose gel. 8D3-streptavidin and NF-κB were radioactively labeled 
with 3H-biotin or 32P-γ-ATP, respectively and incubated for complex formation. 1µl or 
0.5µl of double stranded NF-κB decoys (1µg/µl), about 20,000cpm of 32P-NF-κB and the 
appropriate amounts of bioPEGPEI (MW 6,400Da) (0.1µg/µl) were mixed to yield N/P 
ratios of 3:1 and 6:1, respectively. After a 10min incubation time 8D3-SA (1.3µg/µl) was 
added to the preformed complex to form 8D3-SA/bioPEGPEI/NF-κB ratios of 1/1, 1/3, 
1/9 and 1/27. The complexes were incubated at RT for another 30min. Samples were 
loaded onto a 15 x 15cm 1% agarose gel and separated at 90V for 3h in 1x TAE 
electrophoresis buffer. Each lane was cut in 13 equal pieces (piece 6 was original pocket 
with sample), each piece was digested in 2ml of Soluene (Packard) at 37°C over night 
and counted in organic Scintillation fluid in a beta counter.  
 
2.2.2.7. Interaction of FITC-NF-κB decoys with bEnd5 cells 
Cells were grown in DMEM+ with 10%FCS on 16-well chamber slides (2500 cells/well) 
for 24h prior to treatment. bEnd5 cells were exposed to 0.5µM or 2µM NF-κB decoy 
complexed with bioPEGPEI at a ratio of 6:1 (N/P). The evaluated time points were 2, 4, 
8, 12, and 24h at 37°C in serum-free media. The cells were washed twice after treatment 
in ice-cold PBS pH 7.4 and fixed in 4% paraformaldehyde/PBS for 5min. Cells were 
dehydrated in a graded series of alcohol (70 - 100%) for 1min each. After that, cellular 
accumulation was examined using an epifluorescence microscope. 
 
2.2.2.8. Particle sizing 
Complex size, either of bioPEGPEIODN or 8D3SA-bioPEGPEIODN, in different 
solutions was investigated by photon correlation spectroscopy using a Submicron 
Particle Sizer, Model 380/ZLS. The average particle size distribution was determined by 
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intensity-based Gaussian or multimodal so-called ‘Nicomp’ (non-Gaussian) fit to raw 
data, which had been collected over 15min at 23°C at an angle of 90°. Complex 
solutions were prepared in 10mM PBS pH 7.4, in 10mM PBS pH 7.4 + 10% human 
plasma and DMEM+ without plasma, respectively and measurements started after 
10min, 1h, 2h, 4h, 8h, 24h and 1week. The complex formation was carried out as 
described under 2.2.2.3. in a total volume of 0.2ml containing an ODN concentration of 
10µg/ml. Various N/P ratios were evaluated, ranging from 3:1 to 60:1. 
 
2.2.2.9. Stability tests 
Stability tests were performed to show the durability of various complexes under different 
conditions and at different time points. Several methods were choosen to confirm the 
obtained results. 
Microcentrifugation and trichloro acetic acid (TCA) precipitability 
After labeling of ODNs by T4 polynucleotide kinase radioactive NF-κB decoys were 
complexed with unlabeled ODNs and bioPEGPEI as described under 2.2.2.3. 
Complexes were incubated in DMEM+ for different periods (10min, 1h, 4h, 24h) at 37°C 
or in DMEM+ on bEnd5 cells at 37°C and analyzed by their TCA precipitability. TCA 
precipitation was carried out using 10µl of a carrier DNA (salmon sperm DNA 10mg/ml), 
100µl of 500µl sample and 500µl 20% TCA. The mixture was vortexed and incubated on 
ice for 10min. A centrifugation step was performed at 13,000g for 5min at 4°C and the 
supernatant transferred into 3ml of Econosafe for counting in a beta counter. The pellet 
was dissolved in 500µl of 1N NaOH by vortexing and counted. Another experimental 
series used the combination methods of centrifugation through Ultrafree MC filters 
(Millipore) at 5,000g for 10min and following TCA precipitability both in 10mM PBS pH 
7.4 and DMEM+ with 10% FCS to analyze the extent of dissociation of ODN from its 
complex. Free ODN passes the filter membrane to almost 100%. However, complex 
bound DNA adheres to the membrane. 
 
2.2.3. Stimulation experiments with LPS or TNFα and inhibition of 
activation 
After a growing period of 6 days bEnd5 cells were either stimulated with 
Lipopolysaccharide of E. coli serotype 0111:B4, LD50 = 12.3mg/kg (1µg/ml) or with 
recombinant TNFα (50ng/ml) diluted in DMEM+ medium over a time course of 30, 60, 
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120, 240, and 360min for Northern blot experiments, or for the following periods for 
isolation of nuclear fragments: 1, 5, 10, 60, 120, 240, and 360min. During the stimulation 
periods bEnd5 were incubated at 37°C in a 5% CO2 atmosphere.  
For Northern blot experiments bEnd5 cells were treated with bioPEGPEI/NF-κB or 
8D3SA-bioPEGPEI/NF-κB, respectively, and incubated with different NF-κB 
concentrations (0.1µM - 5µM) over several time frames (4h – 48h) (see 3.3.3.). After 
treatment the medium was aspirated and new DMEM+ with 10% FCS added containing 
the TNFα (50ng/ml). After 4hours of incubation the medium was aspirated and the cells 
prepared for mRNA isolation. 
 
2.2.3.1. Extraction of nuclear fragments and NF-κB gel shift assay 
bEnd5 cells were harvested, washed in icecold phosphate-buffered saline, centrifuged at 
1,850g for 10min and the pellet resuspended in 500µl of buffer A. A recentrifugation step 
was performed at 1,850g for 10min. Cells were resuspended in 80µl buffer A containing 
0.1% TritonX-100 by gentle pipetting. After incubation for 10min on ice, the homogenate 
was centrifuged and the nuclear pellet was washed once with buffer A and resuspended 
in 70µl of ice-cold hypertonic buffer C. This suspension was incubated for 30min on ice 
followed by centrifugation at 13,000g for 30min. The resulting supernatant was stored at 
–80°C as nuclear extract. Protein concentrations were determined by the BCA (Pierce) 
method. To minimize proteolysis, all buffers included 1µl/500µl of a protease inhibitor 
cocktail (SIGMA). 
The NF-κB decoys were 5`-end-labeled with T4 polynucleotide kinase in the presence of 
[γ-32P]ATP (NEN) according to Promega’s protocol. 
For the electrophoretic mobility shift assay, 5µg of nuclear protein were incubated with 
80,000cpm of 32P labeled double-stranded oligodesoxynucleotides in a binding buffer, 
and 1µg of poly (dG:dC) (Pharmacia) for 30min at room temperature. Competition 
studies were performed by adding a 80-fold molar excess of unlabeled double stranded 
oligodesoxynucleotides (1µg) to the binding reaction. Resulting protein-DNA complexes 
(18µl) were resolved on native 5% polyacrylamide gels (20 x 20cm) using a high ionic 
strength buffer (50mM Tris HCl, 380mM glycine, and 2mM EDTA, pH 8.5). The gels 
were run at 250V for 180min, dried under vacuum (55min), and subjected to 
autoradiography (BioMax Kodak). 
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2.2.3.2. mRNA isolation 
After a growing period of 6 or 7 days, respectively, bEnd5 cells were harvested in ice-
cold 20mM PBS pH 7.4 from 6-well plates by using a cell scraper and centrifuged at 
250g for 10min at 4°C. The pellet was then homogenized by pipetting with 1ml lysis 
buffer and genomic DNA was sheared and fragmented through a 21G cannula. The cell 
lysate was centrifuged for 1min at 16,000g and the polyA-RNA directly bound to 
Dynabeads Oligo(dT)25 – paramagnetic, polystyrene beads containing 25 nucleotide 
long chains of deoxythymidylate covalently attached to the bead via a 5` linker group 
(Dynal). The magnetic beads were bound to their magnetic stand, the supernatant was 
taken off and the magnetic beads with the polyA RNA were washed twice in washing 
buffer and once in the same washing buffer without addition of SDS, respectively. 
Elution of mRNA was achieved in 10µl elution buffer for 2min at 65°C. 
 
2.2.3.3. RT-PCR 
One microgram of bEnd5 cell total RNA was reverse transcribed with Superscript II-
reverse transcriptase (GIBCO, BRL) and pd (N)6 random primer hexamers (Pharmacia) 
for 90 min at 42°C. 2µl of reverse transcription product (cDNA) was used for PCR 
without further purification. PCR was a hot start PCR with addition of 2.5U Ampli Taq 
polymerase (5U/µl) at 94°C, and PCR was performed in a total volume of 50µl 
containing 1x PCR buffer II (PE Applied Biosystems) with 2.5mM MgCl2, 0.3mM dNTP 
mix (Pharmacia) and 5‘- or 3‘-primers each of 0.8mM. 35 amplification cycles were 
performed with annealing temperatures of 55°C and annealing time of 40sec. After that 
10µl of PCR products were resolved by electrophoresis on a 1.5% agarose gel. Ethidium 
bromide-stained gels were photographed using a video camera and the Molecular 
Analyzer Software (BioRad) and interpreted. PCR products were purified with the 
QIAquick PCR purification kit according to the instructions of the manufacturer 
(QIAGEN). All amplified and purified DNA probes were sequenced by the Sequencing 
Core Facility at Texas Tech University in Lubbock. 
 
2.2.3.4. pGEM-T vector cloning 
All PCR products were T/A cloned into the pGEM-T vector (Promega) using the polyA 
overhangs of the probe produced by the AmpliTaq Polymerase (PE) and the polyT 
overhangs of the vector. The ligation into this vector was carried out by a T4-DNA ligase 
included in the pGEM-T vector kit (Promega). Vectors were transformed in highly 
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efficient competent cells (E. coli, JM 109, Promega), grown on agar plates and white 
colonies were selected and amplified in LB medium. All protocols were performed 
according to Promega instructions. E. coli were lysed and vector DNA purified with the 
QIAGEN Miniplasmid and Maxiplasmid preparation kits. Selected clones were digested 
by the restriction enzyme BstZI and the cDNA stored at –80°C for further labeling 
procedures. 
 
2.2.3.5. Northern blotting - denaturating formaldehyde gel and hybridization 
The polyA RNA probes were denaturated in denaturation buffer at 65°C for 10min. 2.5-
5µg enriched polyA RNA were separated by electrophoresis in 1x MOPS in denaturating 
agarose gels (1.5% Agarose, 1x MOPS, 2.2M Formaldehyde), transferred to nylon 
membranes (Nytran SuPerCharge, Schleicher & Schuell) by capillary action in 20x SSC 
using the downward transfer system by Schleicher & Schuell over night, and cross-
linked by baking at 80°C for 2h.  
Membranes were pre-hybridized in a solution of 50% formamide, 6x SSPE, 0.5% SDS, 
and 100µg/ml of denaturated salmon sperm DNA for 3 - 4 hours at 42°C. The 
hybridizations were performed with the following 32P-labeled complementary DNA 
probes: All probes were BstZI - BstZI digested fragments complementary to the 
corresponding mouse polyA RNA sequences (ICAM-1, VCAM-1, iNOS, COX-2, IκBα, 
IκBβ and GAPDH). BstZI cut on both polylinker sites of the pGEM vector (Promega). 
The probe labeling procedure was carried out through a random primer labeling kit 
(Prime-it RmTTM, Stratagene) and radioactive labeled [α32P]dCTP (NEN). The probe 
hybridized in a hybridization oven at 42°C for 24 hours. The nylon membranes were 
washed under stringent conditions in 6x SSPE, 0.3% SDS for 15min at 42°C, in 2x 
SSPE, 0.3% SDS for 15min at 42°C, in 1x SSPE, 0.3% SDS for 15min at 42°C and in 
0.5x SSPE, 0.3% SDS for 30min at 50°C. Autoradiographic signals were analyzed by a 
phosphoimager (BIORAD), in combination with densitometric software (Molecular 
Analyzer Software, BIORAD). For photographic reproduction, autoradiograms were 
developed after exposure to x-ray films (Biomax, Kodak). All data were corrected for 
variability in loading by calculation as a ratio to the values obtained with GAPDH. 
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2.2.4.  i. v. pharmacokinetics of bioPEGPEI/NF-κB and 8D3SA-bioPEGPEI/ 
NF-κB 
BALB/c mice were anesthetized with ketamine (100mg/kg) and xylazine (4mg/kg) 
intramuscularly and the right common carotid artery was retrogradely catheterized with 
PE10; 70µl of RHB pH 7.4/0.1%BSA containing either 1µCi of 3H-NF-κB (0.93µg) or the 
combination of 1µCi of 3H-NF-κB (0.93µg) and bioPEGPEI/NF-κB (0.78µg) or 1µCi of 
3
H-NF-κB (0.93µg) and bioPEGPEI/NF-κB (0.78µg) -8D3-SA (25.6µg) were injected into 
the jugular vein and arterial blood was withdrawn from the carotid artery at 0.25, 1, 2, 5, 
10, 20, 30 and 60min after injection of the isotope solution. The complex was formed at 
a N/P ratio of 6:1 and a 8D3-SA/bioPEGPEI ratio of 1:1. The blood samples were 
centrifuged (1,500g, 10min) and plasma was counted for total radioactivity. Mouse 
brains were taken at 60min, solubilized in 2ml Soluene and counted in a beta counter. 
Pharmacokinetic parameters were estimated as described under 2.2.1.3. 
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3. Results 
3.1. Synthesis and characterization of a vector for brain delivery in the 
mouse 
3.1.1. Production and purification of 8D3 hybridoma 
The 8D3 rat hybridoma was generated by Dr. Britta Engelhardt and colleagues at the 
Max Planck Institute for Physiological and Clinical Research, Bad Nauheim, Germany. 
This antibody of the rat IgG2a isotype was obtained by immunization of rats with a murine 
endothelioma cell line and specifically recognizes an antigen on cerebral vessels, which 
has been shown to be the mouse transferrin receptor (Kissel et al., 1998). The 
hybridoma is best grown in serum free media in roller culture and then the antibody was 
purified in 2 steps by ammonium sulfate precipitation followed by affinity chromatography 
on a Protein G column. The final IgG preparation was >95% pure as demonstrated by 
size exclusion HPLC and SDS-PAGE, with a final yield of approximately 20mg/L of 
culture supernatant.  
 
3.1.2. Coupling of the 8D3 antibody to recombinant streptavidin 
An efficient linker strategy between vector and drug moiety is crucial for drug delivery 
applications. The avidin-biotin technology facilitates coupling due to the extremely high 
binding affinity (KD = 10-15 M-1) and to its versatility. The same vector can be used to 
deliver a wide variety of biotinylated ligands. For our experimental procedures a 1:1 
molar conjugate of 8D3 and recombinant streptavidin (SA) was used. Pharmacokinetic 
advantages for in vivo applications of conjugates with neutralized forms of avidin or with 
streptavidin over the strongly cationic native avidin have been described (Bickel et al., 
1994). The linkage was achieved with commercial chemical coupling reagents (Pierce, 
Rockford, IL) as published for the anti rat-transferrin receptor monoclonal antibody OX26 
(Bickel et al., 1993) and described in detail in the ‘Methods’ section. The final reaction 
mixture contained a major fraction of the desired 1:1 molar conjugate, designated 8D3-
SA, along with some higher molecular weight conjugates and residual free 8D3 and 
streptavidin. The FPLC purification on Superdex 200HR was monitored by UV at 280nm 
absorbance and labeling with a trace amount of 3H-biotin on columns. Figure 5 depicts a 
typical chromatographic result. The yield of 8D3-SA is approximately 25 - 30% on a 
protein basis, calculated from the initial amounts of antibody and SA.  
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3.1.3. Pharmacokinetics and brain uptake of 8D3 and 8D3-SA after i.v. 
administration 
The properties of 8D3 as a potential brain delivery vector have been published recently 
(Lee et al., 2000). The pharmacokinetics after i.v. bolus injection of 125I-labeled 8D3 were 
investigated in anesthetized mice. As published, 8D3 demonstrated high uptake into 
brain tissue of up to 3.1 %ID/g (percent of the injected dose per g). Here, the 8D3-SA 
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Figure 5: Purification of 8D3-SA on 2 
Superdex 200 HR 10/30 in series (A, B). A = 
radioactivity in the collected fractions, B = 
corresponding UV-absorbance at 280 nm 
(peak #1 = higher molecular weight 
conjugates, peak #2 = the desired 1:1 molar 
conjugate (arrow in A), peak #3 = uncoupled 
8D3, peak #4 = uncoupled SA. The elution 
profile in C is an analytical rechromatography 
on TSK gel 3000SWXL to verify the purity of 
peak #2 in B. 
Figure 6: Pharmacokinetics of 8D3-SA in 
mice as determined by i.v. bolus injection of 
8D3-SA labeled with 3H-biotin. The brain 
concentration after 60min, the calculated PS-
product, and plasma concentrations are 
shown side by side with corresponding data 
for 125I-8D3. Data are means ± S.E. (n=3). 
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conjugate as a potential drug vector was investigated to characterize its pharmacological 
behavior after i.v. injection into BALB/c mice. In the following table pharmacokinetic 
parameters are compared (see also Figure 6). All data are means ± S.E.. In each 
experimental series three BALB/c mice were injected. 
The pharmacokinetic values were calculated by linear regression fitting using the 
programs BMDP or WinNonlin, respectively.  
 
 8D3                    n=3 8D3-SA              n=3 
Cbrain [% ID/g] 3.1 ± 0.4 2.5 ± 0.3 
AUC(0 – 60min) [% ID . min/ml] 932 ± 57 1035 ± 137 
PSbrain [µl/min/g] 3.3 ± 0.1 2.5 ± 0.3 
VDbrain [µl/g] 263 ± 19 252 ± 28 
 
Table 5: Comparison of pharmacokinetic parameters of 8D3 or 8D3-SA conjugate: cbrain = PS . 
AUC0-60min, AUC – area under the plasma curve, calculated by linear regression fitting (BMDP, 
WinNonlin); PS – brain permeability-surface area PS = (Vd – V0) . cp (60min) / AUC0 – 60min; V0 – 
plasma volume of the brain; cp (60min) – terminal plasma concentration 
 
The data revealed almost unchanged pharmacokinetic properties of 8D3-SA compared 
to the parent antibody. The plasma concentration time course was superimposable. 
Brain uptake rate and brain concentrations reached 80% of the values measured for 
8D3. The values for 8D3 and 8D3-SA conjugate, respectively, are not significantly 
different as shown by t-test.  
We also demonstrated in "capillary depletion" experiments (gentle homogenization and 
density centrifugation in 16% dextran) (Figure 7) that after one hour 33% of the total 
brain concentration of anti-transferrin receptor antibody-SA conjugate was associated 
with the capillary fraction, which is identical with a % ID/g of 0.6. The 8D3-SA could be 
either membrane bound or internalized. In the histogram shown, homogenate represents 
brain tissue and capillaries before density separation. After centrifugation the 
supernatant as the brain tissue and the pellet as the capillary fraction are pictured. The 
data are means ± S.E.. The i.v. bolus injection of the 8D3-SA conjugate was applied to 
three BALB/c mice (n=3). 
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3.1.4. Binding and uptake studies with 8D3 and 8D3-SA using the bEnd5 
brain endothelial cell line 
The bEnd5 endothelioma is derived from mouse brain endothelium and was generated 
by immortalization with polyoma middle T oncogen (Rohnelt et al., 1997). It has been 
successfully used as an in vitro model of the mouse BBB, especially to investigate the 
role of adhesion molecules in T cell transmigration (Laschinger and Engelhardt, 2000; 
Reiss and Engelhardt, 1999). Therefore, the cell line represents a good model for drug 
delivery to brain endothelium and for measuring pharmacologic effects. Evidence for the 
functionality of 8D3-SA as a vector in these bEnd5 cells was obtained by 
immunohistochemistry and tracer binding experiments. First, we visualized the binding of 
8D3 and 8D3-SA to transferrin receptors on bEnd5. Figure 8 demonstrates that 
comparable labeling of bEnd5 cells with either the native antibody or with the 
streptavidin conjugate was obtained. Labeling experiments with 10µg/ml of the native 
8D3 antibody or the synthesized 8D3-SA conjugate showed similar staining patterns. As 
a negative control served the incubation of the biotinylated rabbit anti rat antibody on 
bEnd5 cells without the primary antibody. 
 
 
 
 
Capillary Depletion
Uptake of 8D3-SA into Brain
Homogenate Supernatant Pellet
0.0
0.5
1.0
1.5
2.0
Figure 7: shows a capillary depletion 
experiment 60min after i.v. bolus injection of 
8D3-SA after gentle homogenization of brain 
and separation into capillary pellet and 
postvascular supernatant by dextran density 
centrifugation. Data are expressed as 
percent of the injected dose per g brain and 
show that 33% of total 8D3-SA vector are 
associated with the capillary pellet. 
                                                                                                                             Results            
______________________________________________________________________________________ 
 
49
 
native 8D3 10 µg/mL 
8D3SA 10µg/mL 
negative control 
 
 
 
Second, binding and internalization was measured with 3H-biotin-labeled 8D3-SA. 
Figure 9 shows a representative result of a binding assay. After an incubation time of 
60min a binding of 2.7%/mg protein was measured. A mild acid wash procedure 
revealed that the major fraction (70%) of the cell-associated radioactivity was 
internalized after 15min, 30min or 60min of incubation. Direct evidence for the receptor 
specificity of the binding and uptake was obtained by competition experiments with a 
240-fold molar excess of native 8D3, which resulted in a 90% decreased amount of 3H-
biotin-8D3-SA associated with the bEnd5 cells. In contrast, binding/uptake could not be 
displaced by a corresponding molar excess of the rat-specific TfR antibody, OX26.  
In combination, these results confirm the receptor-mediated uptake mechanism of the 
8D3 antibody and its streptavidin conjugate by brain endothelial cells in vitro.  
 
 
 
 
Figure 8: Immunohistochemistry on bEnd5 cells. The 
cells were grown in 96-well plates and fixed with 3% 
paraform-aldehyde. Endogenous peroxidase and 
unspecific staining were blocked with 0.3% H2O2 and 3% 
bovine serum albumin, respectively. The cells were 
incubated either with 10 µg/ml 8D3 or 8D3-SA. A 
biotinylated rabbit anti-rat IgG antibody was used as a 
secondary antibody. Visualization was performed with 
the avidin-biotin-peroxidase (ABC) method, using 
aminoethylcarbazol (AEC) as a substrate. Negative 
control = without primary antibody. 
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3.2. Polyethylenimines as carriers for oligonucleotides 
3.2.1. Synthesis and characterization of low molecular weight biotinylated 
PEG-PEI 
Dr. Kissel’s group (Institute of Pharmaceutical Technology and Biopharmacy, Philipps-
University Marburg, Germany) has recently developed a small, low-branched PEI 
(molecular weight, 2,700Da) with favorable characteristics for DNA delivery in vitro and 
in vivo: very narrow size distribution, superior transfection efficiency in vitro, and very low 
cellular toxicity compared to commercial PEI formulations (Fischer et al., 1999). A graft 
copolymer with biotinylated PEG (designated as bioPEGPEI) was synthesized. The 
biotin-PEG serves two purposes: (1) it enables coupling to our 8D3-SA vector. Such 
biotinylated PEG derivatives have been successfully used for coupling of cationic 
macromolecules such as brain derived nerve growth factor to streptavidin-based vectors 
(Wu et al., 1999). (2) as known from pharmacokinetic studies (Zalipsky et al., 1995), 
PEGylation improves the stability and pharmacokinetics of diverse macromolecular 
conjugates.  
pH 7.4 wash pH 3 wash
0
1
2
3 15 min
30 min
60 min
Figure 9: Binding and uptake studies with 
bEnd5 cells demonstrate a time dependent 
increase of both binding and internalization 
as shown by mild acid wash. After 60min a 
binding of 2.7%/mg protein was observed. 
The pH 3-solution removes cell surface 
bound 3H-biotin-8D3SA and the results 
after acid wash represent internalized 
tracer. The internalization is expressed as 
a percentage of total binding. Data are 
standardized by the protein measurement 
of the solubilized cells. 
Incubation of bEnd5 cells with 3H- 8D3-SA 
and additional unlabeled 8D3 or OX26 
(240-fold molar excess) for competition 
studies showed a 90% decrease in binding 
for 8D3. However, no competition by the 
anti-rat Ab OX26 was seen. 
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The graft copolymer was synthesized at a 1:1 molar ratio from biotin-PEG (molecular 
weight = 3,400Da, Shearwater Polymers) carrying a single reactive N-
hydroxysuccinimide ester group (NHS) at the opposing end of the linear PEG chain, and 
our low molecular weight PEI (MW = 2,700Da). Equimolar amounts of biotin-PEG-
CO2NHS (3,700Da) (0.034mmol in 40ml CHCl3) and Low Molecular Weight PEI 
(2,700Da) (0.034mmol in 25ml CHCl3) were added together dropwise under vigorous 
stirring. The reaction mixture was boiled for 18h. No non-reacted biotin-PEG was left as 
determined by NMR and size exclusion chromatography of the reaction mixture. The 
synthesis of the bioPEGPEI was carried out in Dr. Kissel’s laboratory. The 
spectrophotometric HABA assay demonstrated that bioPEGPEI retained full binding 
affinity for streptavidin (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
3.2.2. Complex formation and Retardation assays 
Different molar ratios of PEI amine to DNA phosphate (N/P ratio) were tested for 
complexation of ODN (NF-κB decoy) by bioPEGPEI and analyzed in retardation assays 
on polyacrylamide and agarose gels. Figure 11 demonstrates that bioPEGPEI readily 
formed complexes with the ODN in 10mM PBS pH 7.4. At N/P = 3:1 virtually all ODN is 
Figure 10: HABA assays for measurement of biotin concentrations. The biotin analog HABA 
binds weakly to streptavidin, forming a colored complex in solution. HABA can be displaced by 
increasing concentrations of biotin (x-axis), as detected by a proportional change in absorbance 
at 500 nm (y-axis). Addition in equimolar amounts of bioPEG (biotinylated PEG MW 3,400), 
bioPEGPEI (copolymer of bioPEG and PEI MW 2,700), bioPEGPEI-ODN (complex of bioPEGPEI 
with NFκB decoy ODN) resulted in comparable displacement curves. The slopes of the 
regression lines were not significantly different from the biotin standard (black), indicating that the 
biotin moiety in bioPEG and bioPEGPEI is fully available for binding, even after complex 
formation with the ODN. 
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bound, and at higher N/P ratios no free ODN is detectable. ODN in complex form is 
protected from nucleases in plasma as shown in Figure 11B. 
 A 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: (A) Different N/P ratios ranging from 1:1 to 7:1 were investigated on an ethidium 
bromide stained 1% agarose gel. Lane 1 shows 4µg of a free ODN, incompletely complexed by 
bioPEGPEI at ratios 1:1 to 2.5:1 and completely bound at higher ratios. Pocket staining revealed 
neutral or cationic complexes. 
Non-denaturating 20% poly-acrylamide gels stained with SYBR Gold for visualization of DNA. 
The samples in (B) were loaded as follows: lane 1 = double-stranded ODN (NF-κB decoy), 2 to 4 
= bioPEGPEI-ODN complex at N/P ratios of 3:1, 6:1, and 10:1. The position where the sample 
was loaded is indicated by the arrow, the double arrow shows the migration of free double-
stranded ODN. At N/P of 6:1 and 10:1 there was no free ODN detectable.  
(C) demonstrates the stability in 20% human plasma of the bioPEGPEIODN complexes with N/P 
ratios of 6:1 (lanes 1-3) and 10:1 (lanes 4-6). The samples were incubated at 37°C for 0 min (lane 
1 and 4) 30 min (lane 2 and 5) or 120 min (lane 3 and 6) before application to the gel. 
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3.2.3. Binding characteristics of 8D3-SA to its ligand bioPEGPEI/NF-κB 
The targeting vector 8D3-SA was radioactively labeled with 3H-biotin and conjugated 
with bioPEGPEI/NF-κB at different molar ratios to investigate its separation in an electric 
field by electrophoresis. After a 3h electrophoresis at 90V the free 8D3-SA moved from 
its origin (pocket, gel slice #6) and accumulated in gel slice #9 (Figure 12).  
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Figure 12: Migration of 8D3-
SAbioPEGPEI/NF-κB on a 1% 
agarose gel N/P = 3:1. The 
agarose gel was cut into 13 equal 
gel slices and each slice was 
measured in a beta counter. The 
first panel shows the 8D3-SA 
without conjugation, all the other 
panels show conjugation at a drug 
to antibodyconjugate ratio of 1/1, 
1/3, 1/9 and 1/27. 
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The same studies as for the free 8D3-SA, were repeated after conjugation of vector with 
its ligand at the following vector/ligand ratios of 1/1, 1/3, 1/9 and 1/27. Due to the 
neutral/cationic characteristics of the bioPEGPEI/NF-κB at ratio 3:1, a shifting to gel slice 
#8 is visible. Particularly, a conjugation of 1/1 seems to form a distinct peak, whereas all 
the other ratios obtained more indistinct peaks reaching slices #9 to 13. We obtained 
similar results studying bioPEGPEI/NF-κB ratios of 6:1. Noticeable is a slight shift in 
mobility to gel slice #7 (Figure 13). 
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Figure 13: Comparable binding and separation behavior of complexes is shown at a N/P ratio of 
6:1. However, a shifting of the peak fraction is noticed in conjugates at ratios of 1:9 and 1:27, 
suggesting that increasing amounts of PEI prevent a separation as shown at ratios 1:1 and 1:3. 
 
 
The same samples were analyzed by counting the radioactive labeled 32P-NF-κB part of 
this complex in a beta counter. Broad distribution with a hardly visible peak in slice #8 is 
shown at 8D3SA-bioPEGPEI/NF-κB ratio of 1/1. The small amount of radioactivity in the 
sample could explain the lack of a prominent peak (compare cpm values to the following 
samples). Distinct peaks appear at ratios 1/3 and1/9 in gel slice #7, corresponding to 3H-
biotin counts seen at ratio 6:1, but shifted from #8 to #7, if compared to ratio 3:1. Ideally, 
- + - +
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both radioactivities (3H/32P) should have their peak fraction in the same slice to proof the 
tight binding of all components. Due to its strong negative charge, free NF-κB would 
expect to appear in higher slice numbers (Figure 14). 
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Figure 14: 32P-NF-κB cpm of each slice were counted and presented in the diagram to compare 
peak fractions at a N/P ratio of 3:1 and different 8D3-SA to bioPEGPEI/NF-κB ratios. The first 
panel reveals a relatively homogenous distribution of ODN compared to the panels at higher 
antibody to ligand ratio. The behavior of the ODN’s in this case is not explainable, it can only be 
suspected that the increasing amount of PEI has a further influence on the stability of DNA in its 
conformation independent from the ratio, in which the DNA was complexed before (3:1). The 
variable cpm numbers are due to different amounts of ODN entering the conjugation reaction 
between antibody and ligand. 
 
When complexes formed at the 6:1 ratio were investigated, they revealed exactly the 
same behavior as shown for the 3:1 ratio. Moreover, peaks in gel slices #7 show clearly, 
that vector and ligand are tightly associated. A PEI excess seems to have a negative 
influence on the separation properties of the conjugate as shown by enhanced conjugate 
accumulation in slice #6 (pocket) (Figure 15). 
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Figure 15: Diagrams show an analogue picture as seen for N/P ratios of 3:1 in Figure 14. 
Distinct peaks are formed at antibody to ligand ratio of 1/3 and 1/9, resulting in an excess of PEI 
at ratio 1/27 sitting in the pocket (slice #6). Due to low amount of activity in the first panel (ratio 
1/1), no distinct peak could be detected. 
 
 
 
3.2.4. Vector-mediated increase in cellular uptake 
Quantitative uptake experiments with 32P-labeled ODN (5' labeling with T4 
polynucleotide kinase and γ-32P-ATP) were performed with bEnd5 cells in 24-well plates. 
The tracer was added in 0.5ml cell culture medium and incubated for various times at 
37°C. Figure 16 depicts the results of a 60min uptake study. Less than 0.2% of the 
activity was associated with cells when free ODN was used. The bioPEGPEIODN 
complex showed binding and uptake of 2%, and this was further increased 3-fold by the 
targeting to transferrin receptors with 8D3-SA (8D3SA/bioPEGPEIODN = 1:1). In a 
separate experimental series a mild acid wash at the end of the incubation was used to 
differentiate surface bound and internalized tracer. For bioPEGPEIODN complexes with 
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8D3-SA we found >90% of the total activity as internalized fraction at incubation times of 
more than 10 min, which is in good agreement with the data obtained for 3H-biotin-8D3-
SA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5. Interaction of FITC-NF-κB decoys with bEnd5 cells 
Fluorescence microscopic studies with FITC-labeled NF-κB decoys 0.5µM confirmed the 
cellular uptake of 8D3SA-bioPEGPEI/NF-κB by bEnd5 cells (Figure 17). At early times 
(30min incubation at 37°C) labeling of the plasma membranes, at later time points (4h, 
8h) uptake of fluorescent dye into the nucleus could be observed. The pictures were 
taken on a Nikon inverted fluorescence microscope with a 40time lens. The same 
experiments were carried out without vector. At the fluorescence microscopy level we 
could not recognize differences in staining patterns. Also uptake studies with 2µM ODN 
did not display any visible differences. 
 
 
 
Figure 16: Uptake of 32P-labeled ODN by 
bEnd5 cells after 60min (mean ± SD, 
n=3). The N/P ratio of the bioPEGPEI-
ODN complexes was 3:1. The ODN 
tracer concentrations were adjusted to 
0.2µM. After the incubation period cells 
were washed 3x with cold medium, 
solubilized in 1M NaOH and counted in 
scintillation fluid in a liquid scintillation 
counter. 0.0
2.5
5.0
7.5
Control = free NF-κB decoy 8D3SA-bioPEGPEI/NF-κB 
30min 
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Figure 17: The fluorescence microscopy pictures show the incubation of 8D3SA-bioPEGPEI/NF-
κB 0.5µM on bEnd5 cells at various incubation times. Free NF-κB decoys served as a negative 
control. Pictures were taken with a 40time lens. 
 
3.2.6. Particle sizing  
In the past, several experimental studies investigating particle sizes of PEI-ODN 
complexes under different salt conditions proved difficult, because of rapid aggregation 
of polyplexes with each other (Tang and Szoka, 1997). Pegylation of PEI not only 
improves pharmacokinetic stability in vivo, it also prevents the non-specific interaction 
with blood components, such as erythrocytes and plasma proteins (Ogris et al., 1999). 
Moreover, this PEI modification should enable its measurement under different 
incubation conditions, while preventing its aggregation. Our first measurements were 
performed in 10mM PBS at a pH of 7.4 and N/P ratios ranging from 3:1 to 60:1 to show 
a possible size change (Figure 18). At a ratio of 3:1 complexes seem to be very 
constant in size (120 - 140nm) over time. Particle sizes in this range can be expected to 
be compatible with the endosomal compartment. 6:1 ratio complexes proved even 
smaller with narrower Gaussian distribution, demonstrating a higher complexation of PEI 
and ODN. However, with further increasing N/P ratios the complex size increased.  
Samples were stored at 4°C and a repeat measurement was carried out after 4w. There 
was no change in complex size. 
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Stability of a bioPEGPEI/NF-κB complex in PBS (pH 7.4) at different N/P ratios 
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Figure 18: Size measurements of 
bioPEGPEI/NFκB complexes at 
different N/P ratios incubated in 
10mM PBS pH 7.4 from 10min to 1w 
(samples were stored at 4°C) after 
complex formation. Values are 
means ± S.E. with n=3. Gaussian 
S.E. are means of n=3 obtained 
values. 
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In a second step we tested the influence of coupling our targeting vector to the 
DNA/polymer complex by incubating 8D3-SA (MW 210kDa) with bioPEGPEI/NFκB after 
complex formation for 15min (Figure 19). From the results obtained in the first study we 
chose the 6:1 ratio for further experiments. The diagram shows an average increase in 
complex size of 40nm compared to the unconjugated complex (see Figure 18). After 1w 
a moderate decrease of complex size by 30nm could be observed compared to the 24h 
measurement, which may be caused by loosening of complex formation rather than 
dissociation of vector and ligand (the dissociation time of biotin and streptavidin is 90 
days). 
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Stability of an 8D3-SAbioPEGPEI/NFκB complex in PBS (pH 7.4) at N/P ratio of 6:1 
Figure 19: shows a representative 
picture of a size and stability test after 
complex formation of drug and its 
vector at a N/P ratio of 6:1 and molar 
8D3SA/bioPEGPEI ratio of 1:1. 
Complex sizes appear to be constant 
over a time frame of 24h, after 1w 
smaller complexes are visible with 
decreasing Gaussian distribution. 
Stability of a bioPEGPEI/NFκB complex in DMEM+ (w/o plasma) at N/P ratio of 6:1 
Figure 20: bioPEGPEI/NFκB com-
plexes are shown after incubation in 
DMEM+ as they appear under in vitro 
conditions. The complex size increased 
over 1w, suggesting a time dependent 
uptake of salts contained in the 
DMEM+. 
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Medium salts also have an influence on size behavior as shown in Figure 20. In contrast 
to all other results obtained, sizes changed over time significantly. Starting at 160nm 
after 10min of complex incubation, particle sized increased to about 280nm after 1w. 
These findings may be explained by continuous incorporation of salt ions into the 
polyplex. 
 
3.2.7. TCA (Trichloro acetic acid) precipitation and ultrafiltration 
The stability tests already mentioned under 3.2.2. were extended by incubating 
complexes in different media and over several time frames. Ultrafiltration and trichloro 
acetic acid precipitation were used as analytical tools. 
bioPEGPEI/NF-κB complexes were incubated either in 10mM PBS or DMEM+ with 10% 
FCS over 10min, 1h, 4h or 24h at 37°C and filtered through an Ultrafree MC (Millipore) 
unit at 5000g for 10min. Free NF-κB passes this filter to almost 100%, complexes 
adhere to the filter membrane (see Figure 21). Therefore, this method can be used to 
estimate the percentage of ODN, which is released from its complex after the various 
incubation times. A TCA precipitability test of NF-κB decoy or its complex was used to 
check for the purity of tracer after labeling and for the stability of the complex, 
respectively. The mean TCA of labeled probe after incubation in PBS was 96.4%, and 
after incubation in DMEM + with 10% FCS was 88.0%, yielding values of 94.8% after 
incubation in PBS and 89.2% after incubation in DMEM + with 10% FCS for 24h, 
respectively. The results of this 24h experiment show that the time and the incubation 
medium do not decrease stability, supporting the results of native PAGE (section 3.2.2.). 
In a second experimental series the probability of alteration of the complex by incubation 
on bEnd5 cells was investigated. The experiments were performed in the same manner 
as described, incubating the complex in DMEM + 10% FCS in an Eppendorf tube or on 
bEnd5 cells for the same periods as above (Figure 22). Surprisingly, after 24h of 
incubation we could see an almost complete release of ODN (96.7%) from its complex 
caused by cell activity. Incubation times of 10min and 1h revealed similar results as 
obtained for experiments carried out in an Eppendorf tube.  
The measurement of TCA precipitability correlated well with the filtration experiments: 
the TCA precipitability of freshly labeled ODN was 94%, decreasing only slightly to 
92.7% after 10min and 87.5% after 24h. In contrast, incubation on cells decreased 
precipitability from the medium to 34.8% after 24h.  
 
                                                                                                                             Results            
______________________________________________________________________________________ 
 
62
 
 
 
10mM PBS DMEM + 10% FCS
0
20
40
60
80
100
NFκB
bioPEGPEINFκB 10min at 37°C
bioPEGPEINFκB 1h at 37°C
bioPEGPEINFκB 4h at 37°C
bioPEGPEINFκB 24h at 37°C
fr
ee
 N
F κ
B 
in
 %
Figure 21: 100% of free NF-κB decoy incubated in PBS pass through the ultrafiltration 
membrane. Free ODN incubated in DMEM + 10% FCS pass to 70%, due to partial binding of 
ODN to plasma proteins and their retention by the filter. In contrast, only 1.1% of total ODN in 
complex with bioPEGPEI pass through the membrane after a 10min incubation at 37°C in PBS. 
There is only a minor increase to 3.4% after 24h incubation. The result is similar after incubation 
in DMEM with 10% FCS.  
 
 
 
DMEM+10%FCS DMEM+10% FCS on bEnd5 
0
20
40
60
80
100
NF-κB
bioPEGPEINF-κB 10min at 37°C
bioPEGPEINF-κB 1h at 37°C
bioPEGPEONF-κB 4h at 37°C
bioPEGPEINF-κB 24h at 37°C
fr
ee
 N
F-
κB
 in
 %
 
 
Figure 22: Comparison of complex stability after 10min, 1h, 4h and 24h of incubation either 
without or with bEnd5 cells.  
 
 
 
 
                                                                                                                             Results            
______________________________________________________________________________________ 
 
63
 
3.3. Investigation of inflammatory markers influenced by activation of  
NF-κB 
3.3.1. NF-κB gel shift assays 
As a method to directly show the modulation of the transcription factor by stimulation 
with Lipopolysaccharide (LPS) or TNFα, we utilized electrophoretic mobility shift assays 
(EMSA). The cells were grown in 6-well plates. An inflammatory response was provoked 
by addition of bacterial LPS and TNFα (1µg/mL and 50ng/mL, respectively) or LPS 
alone to the culture media, which activates the NF-κB transcription factor. Nuclear 
extracts were prepared from the cells after various times and incubated with 32P-labeled 
NF-κB decoy oligo (Bragonzi et al., 1999). The ODN sequence used in these 
experiments contains the NF-κB binding cis-element of the murine VCAM-1 promoter 
(Cybulsky et al. 1993) and is a 20-mer phosphodiester ODN with the sequence 5'-CCT 
TGA AGG GAT TTC CCT CC-3' (κB-consensus site bolded and underlined). A 
scrambled ODN sequence (5'-TTG CCG TAC CTG ACT TAG CC-3') was used as a 
control. The ODNs were custom synthesized (MWG Biotech) as single-stranded 
sequences and were annealed with the complementary 20-mer prior to use. The result 
of the binding reactions of labeled NF-κB decoy with nuclear extracts and the 
electrophoresis is shown in Figure 23. NF-κB activity was just faintly detectable in the 
control cells (= 0min), but showed the expected strong signals after 1min and 5min of 
stimulation. In the 60min and 120min samples a second peak of activity appeared. The 
specific bands representing NF-κB binding activity were verified by competition with 
unlabeled specific ODN. There was no competition with an equal excess of the 
scrambled ODN sequence detectable (not shown). 
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Figure 23: depicts a typical picture of an EMSA after stimulation of bEnd5 cells with TNFα 
(50ng/ml) and LPS (1µg/ml). NF-κB is constitutively active at a low level, its activity increases  
after 1min and 5min of stimulation, reaching the first peak after 5min. A second peak can be seen 
after 120min, followed by a decrease to almost basal levels after 360min. A 80-fold molar excess 
of non-labeled NF-κB decoy prevents binding of 32P-NF-κB decoy to its transcription factor. 
However, non-specific bands (arrow heads) remain visible, supporting the specificity of the 
competition. 
 
 
 
 
We could obtain a different activation pattern after sole stimulation by LPS. The 
maximum peak of activation occurred after 5min and 10min, respectively, declining to 
basal levels after 120min (Figure 24). We could not show any biphasic activation as 
seen after combined LPS/TNFα activation.  
These results form a base for continuing investigations regarding activation/inhibition 
experiments after targeted treatment with 8D3SA-bioPEGPEI/NF-κB decoys. 
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Figure 24: The autoradiogram represents an activation pattern after stimulation with LPS 
(1µg/ml) alone. A maximum of stimulation can be observed after 5min and 10min, respectively, 
resulting in a decrease after 120min. Competition studies were performed as described in the 
picture legend above.  
 
 
3.3.2. Northern blots for quantification of gene expression related to 
inflammation 
We generated the probes required for detection on Northern blots of a select group of 
transcripts involved in inflammation: adhesion molecules ICAM-1 and VCAM-1; inducible 
nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and the inhibitor components 
of NF-κB complexes, IκBα and IκBβ. The measurements of these mRNAs serve as 
quantitative parameters for the pharmacological effect of oligodeoxynucleotide drugs. 
Data have been obtained in the bEnd5 in vitro model by treatment with LPS, TNFα and 
TNFα/LPS as described for NF-κB shift assays. After various times of stimulation, bEnd5 
cells grown in 6-well plates were harvested by scraping, lysed in 1% SDS buffer and 
mRNA was extracted for Northern blotting.  
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Our first stimulation experiments were carried out with LPS 1µg/ml. The activation 
patterns changed over the observed time period of 360min, reaching their peak values at 
120min. In most cases, after 120min values declined to original values obtained at time 
0min. The gene expression was upregulated 7.7-fold for ICAM-1 and 5-fold for VCAM-1 
and IκBα. The maximum level for iNOS was reached after 240min (2-fold). Transcripts 
for COX-2 and IκBβ remained nearly constant. The evaluations were performed by 
standardization to the signal for the house-keeping gene GAPDH. 
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Figure 25: Northern blots of mRNA isolated from bEnd5 cells after sole stimulation with LPS 
1µg/ml. Time after stimulation is given on the x-axis. The bar graphs show the ratios relative to 
time = 0 after standardization to the GAPDH signal. Activation peaks of investigated mRNAs 
appear at 120min. VCAM-1: The band at lower molecular weight represents the splice variant for 
the truncated GPI-anchored form (Cybulsky et al. 1993). 
 
In addition to these observations we hybridized TNFα (50ng/ml) stimulated mRNA blots 
with the same probes and detected different stimulation patterns compared to LPS 
activation. As shown in Figure 26 the most obvious differences in stimulation could be 
measured for ICAM-1 and VCAM-1, suggesting that upregulation of these adhesion 
molecules is more responsive to TNFα. ICAM-1 could be stimulated by LPS 7.7-fold, by 
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TNFα about 32-fold and VCAM-1 was activated 5-fold, as compared to a 28-fold 
elevation by TNFα. Most investigated genes reached their peak levels at the end of the 
covered time period of 360min. 
Results obtained point out a major role of TNFα for upregulation of gene expression 
involved in inflammatory processes in this brain endothelial cell line. 
TNF 
 
 
       0m
in
30
mi
n
60
mi
n
12
0m
in
24
0m
in
36
0m
in
0
10
20
30
40
ra
tio
                  0m
in
30
mi
n
60
mi
n
12
0m
in
24
0m
in
36
0m
in
0
5
10
15
ra
tio
                      0m
in
30
mi
n
60
mi
n
12
0m
in
24
0m
in
36
0m
in
0.0
2.5
5.0
7.5
ra
tio
 
 
 
 
        0
mi
n
30
mi
n
60
mi
n
12
0m
in
24
0m
in
36
0m
in
0
10
20
30
ra
tio
                   0
mi
n
30
mi
n
60
mi
n
12
0m
in
24
0m
in
36
0m
in
0.0
0.5
1.0
1.5
2.0
ra
tio
                      0m
in
30
mi
n
60
mi
n
12
0m
in
24
0m
in
36
0m
in
0.0
0.5
1.0
1.5
2.0
2.5
ra
tio
  
Figure 26: Northern blots of mRNA isolated from bEnd5 cells after sole stimulation with TNFα 
50ng/ml. Time after stimulation is given on the x-axis. The bar graphs show the ratios relative to 
time = 0 after standardization to the GAPDH signal. An increasing stimulation pattern is shown for 
almost all mRNAs, reaching their peak levels at 360min (see also Figure 27 for comparison 
studies). 
 
Figure 27 depicts the time course found in stimulation experiments with TNFα/LPS in 
combination. As shown, all messages were increasingly stimulated within the time frame 
covered in this study (0-360 min) and could compared with results we obtained from 
Northern blots with sole TNFα activation. The maximum levels of stimulation for the 
different mRNA species, compared to baseline, ranged from 2-fold (IκBβ) to 40-fold 
(VCAM-1). The robust signals and the wide dynamic range seen in our experiments 
confirm that this system is well suited for detecting pharmacological modulations in gene 
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expression. We expected this selection of gene transcripts to be adequate for monitoring 
the effects of our NF-κB inhibitor. 
TNF/LPS 
Figure 27: Northern blots of mRNA isolated from bEnd5 cells after stimulation with LPS and 
TNFα. Time after stimulation is given on the x-axis. The bar graphs show the ratios relative to 
time = 0 after standardization to the GAPDH signal.  
 
 
3.3.3. Inhibition of VCAM-1 expression after NF-κB decoy treatment  
To further characterize the inhibition of immune response after NF-κB decoy treatment 
we chose to evaluate the expression patterns of VCAM-1. VCAM-1 shows an abundant 
expression after stimulation with TNFα (50ng/ml) (see Figure 26 and 27).  
Moreover, besides the predominant form of VCAM as a seven immunoglobulin domain 
containing transmembrane protein (Cybulsky et al., 1991), there is a second transcript 
containing only the first three immunoglobulin domains (Terry et al., 1993). This 
truncated molecule contains the message for a glycosylphosphatidylinositol (GPI)-
anchored form of VCAM-1. 
In our experimental studies we investigated the expression patterns of both isoforms in 
terms of time, concentration of applied oligodeoxynucleotides, and deprivation of FCS. 
First, we performed all our experiments with the non-targeted conjugate bioPEGPEI/NF-
κB at a N/P ratio of 6:1. Our fluorescence microscopy studies revealed uptake of non-
targeted complex into bEnd5 cells. However, with this method we could not see any 
significant difference of uptake between targeted (8D3 MAb) and non-targeted delivery 
(Figure 17). In Figure 28 the incubation of cells with medium without or with FCS, 
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respectively, served as a control and was set to 100%. After treatment of bEnd5 cells 
with our drug over 4h, 12h, 24h or 48h cells were harvested and mRNA of 3 wells of a 6-
well plate for each time point was isolated. Northern blot studies were performed and the 
density of obtained bands was calculated using the Molecular Analyst software 
(BIORAD). The ratios of VCAM-1 isoform1 and isoform2 were estimated after 
normalization to the house-keeping gene GAPDH. The concentration of NF-κB decoy 
applied in these series was 2µM. First, the cells were incubated with decoys as 
described, then the medium was removed and replaced by fresh medium containing 
TNFα (50ng/ml) for 4h. No activation of expression without TNFα stimulation was found, 
neither for isoform1 nor for isoform2. Interestingly, after treatment of cells with 
bioPEGPEI/NF-κB for 4h we could recognize a slight stimulation of VCAM-1 of about 
20% in comparison to our control. After incubation with drug over 12h, 24h, and 48h the 
expression levels decreased continuously to 5 to 15% of the original value. The 
expression patterns for the two isoforms were similar, but activation of isoform2 was at a 
lower level compared to the density of bands for isoform1. We could show that the 
absence or presence of FCS from the medium had no influence on the ability of drug to 
reduce the TNFα-dependent activation. 
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Figure 28: Northern blot experiments performed under addition of bioPEGPEI/NF-κB drug to 
medium for several incubation times of 4h, 12h, 24h, and 48h. Incubation of bEnd5 cells with 
medium +/-10% FCS and +/-TNFα (50ng/ml) served as starting points for treatment studies. 
Expression patterns of VCAM-1 isoform1 and isoform2 are described in two separate diagrams. 
On the x-axis treatment and incubation times are shown, the y-Axis describes the percentage of 
activation compared to the original value (100%). ratio = VCAM-1/GAPDH. 
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As the second part of our investigations we performed concentration-effect studies using 
0.1µM, 0.5µM, 1µM, 2µM, and 5µM of NF-κB complexed with bioPEGPEI (N/P = 6:1). 
The experiments were carried out with FCS deprived medium. (see Figure 29). bEnd5 
cells were incubated for 24h. At this time point we saw a significant inhibition of 
activation by bioPEGPEI/NF-κB. Surprisingly, after incubation of cells with 0.1µM and 
0.5µM of oligodeoxynucleotide a slight increase, up to 40% for isoform1 and 20% for 
isoform2 at a concentration of 0.1µM, was detected, decreasing to 20% for isoform1 and 
3% for isoform2 of the original value after incubation with 5µM of NF-κB decoy. The 
signals for isoform2 were weaker than the signals for isoform1 as already seen in Figure 
28. 
 
                                                 
24
h m
ed
ium
 - F
CS
 
24
h m
ed
ium
 - F
CS
24
h P
EI
NF
kB
 0.
1µM
 
24
h P
EI
NF
kB
 0.
5µM
 
24
h P
EI
NF
kB
 1
µM
 
24
h P
EI
NF
kB
 2
µM
 
24
h P
EI
NF
κB 
5µM
 
0
20
40
60
80
100
120
140
160 - TNF
+ TNF 4h
ra
tio
  %
24
h m
ed
ium
 - F
CS
24
h m
ed
ium
 - F
CS
24
h P
EI
NF
kB
 0.
1µM
 
24
h P
EI
NF
kB
 0.
5µM
 
24
h P
EI
NF
kB
 1µ
M 
24
h P
EI
NF
kB
 2µ
M 
24
h P
EI
NF
kB
 5µ
M 
0
20
40
60
80
100
120
- TNF
+ TNF 4h
ra
tio
  %
 
Figure 29: Evaluation of concentration curves using bioPEGPEI/NF-κB 6:1 with different 
concentrations of NF-κB of 0.1µM, 0.5µM, 1µM, 2µM, and 5µM at a time point of 24h. Incubation 
of bEnd5 cells with medium without FCS and +/-TNFα (50ng/ml) served as starting points for 
treatment studies. Expression patterns of VCAM-1 isoform1 and isoform2 are described in two 
separate diagrams. On the x-axis treatment and incubation times are shown, the y-Axis describes 
the percentage of activation compared to the original value (100%). ratio = VCAM-1/GAPDH. 
Results represent one of two experiments carried out with similar treatment. 
 
 
Repeating experiments with similar formulation of a question were carried out to control 
a possible toxic effect leading to an activation of VCAM-1 expression by bioPEGPEI/NF-
κB or NF-κB alone without TNFα activation Figure 30. Concentrations of 0.1µM were 
chosen, because of their stimulating effects seen in the previous studies. Neither 
bioPEGPEI/NF-κB nor NF-κB showed any activating effect when applied without 
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following TNFα activation, suggesting no toxic effect of bioPEGPEI or NF-κB at this 
concentration. The expression values of different oligodeoxynucleotide concentrations 
behaved similar to values seen in Figure 29. Concentrations of 5µM were able to 
completely suppress activation of VCAM-1 isoforms. 
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Figure 30: Evaluation of concentration curves using bioPEGPEI/NF-κB 6:1 with different 
concentrations of NF-κB of 0.1µM, 0.5µM, 1µM, 2µM, and 5µM at a time point of 24h. Incubation 
of bEnd5 cells with medium without FCS and +/-TNFα (50ng/ml) served as starting points for 
treatment studies. In addition, for studies of toxic effects cells were treated with 0.1µM NF-κB 
complexed with bioPEGPEI or NF-κB alone. Expression patterns of VCAM-1 isoform1 and 
isoform2 are described in two separate diagrams. On the x-axis treatment and incubation times 
are shown, the y-Axis describes the percentage of activation compared to the original value 
(100%). ratio = VCAM-1/GAPDH. Results represent one of two experiments carried out with 
similar treatment. 
 
In our next studies the bioPEGPEI/NF-κB (6:1) complex was conjugated with the 8D3 
anti-transferrin receptor MAb to compare uptake seen in preliminary experiments and 
using the targeted vector Figure 31. The 8D3 streptavidin conjugate was incubated with 
bioPEGPEI/NF-κB for 15min for coupling and bEnd5 cells were treated as described 
above. We depicted early time points (8h) and concentrations of 0.5µM and 1µM to 
show significant differences in inhibition patterns. For VCAM-1 isoform1 a reduction of 
expression at a concentration of NF-κB decoy of 0.5µM was seen for the targeted 
delivery – 117% 0.5µM bioPEGPEI/NF-κB, and 60% 0.5 µM 8D3SAbioPEGPEI/NF-κB 
compared to the original value set to 100%. This was a difference of 57%. The same 
VCAM-1 
(isoform1) 
GAPDH 
VCAM-1 
(isoform2) 
GAPDH 
                                                                                                                             Results            
______________________________________________________________________________________ 
 
72
 
picture was observed for a concentration of 1µM NF-κB – 107% bioPEGPEI/NF-κB, and 
53% 1µM 8D3SAbioPEGPEI/NF-κB – a difference of 54%. For VCAM-1 isoform2 a 
stronger inhibition could be reached. However, the differences between targeted and 
non-targeted delivery were less distinct than for isoform1. With bioPEGPEI/NF-κB 0.5µM 
an inhibition to 58% was reached, compared to 31% for the vector-mediated delivery 
(difference 27%). For concentrations of 1µM bioPEGPEI/NF-κB an inhibition to 50% 
could be shown compared to 27% for the targeted delivery (difference 23%). Even 
incubation of bEnd5 cells with NF-κB decoy concentrations of 5µM under the same 
conditions did not reveal a reduction of activation comparable to the tissue directed 
delivery. 
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Figure 31: Influence of targeted delivery with 8D3SAbioPEGPEI/NF-κB complex at 
concentrations of 0.5µM and 1µM compared to non-targeted delivery at the same or higher 
concentrations after 8h of incubation. Incubation of bEnd5 cells with medium without FCS and +/-
TNFα (50ng/ml) served as starting points for treatment studies. Expression patterns of VCAM-1 
isoform1 and isoform2 are described in two separate diagrams. On the x-axis treatment and 
incubation times are shown, the y-Axis describes the percentage of activation compared to the 
original value (100%). ratio = VCAM-1/GAPDH. 
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3.4. i.v. pharmacokinetics of bioPEGPEI/NF-κB and 8D3SA-bioPEGPEI/ 
NF-κB 
In order to investigate the pharmacological behavior of bioPEGPEI/NF-κB after i.v. 
injection into BALB/c mice, we labeled NF-κB decoy with 3H and added non-labeled 
ODN for complex formation at different N/P ratios. Complexes with and without vector 
were injected into the jugular vein and blood samples were collected from 25sec to 
60min to determine the plasma concentration time course. 
Figure 32 shows the plasma concentration time course and TCA precipitability of the 
various tracers in the corresponding plasma samples. All plasma concentrations 
represent only the TCA precipitable fraction. They were fitted with a bi-exponential 
disposition function. The initial, rapid distribution phase (α-phase) is characterized by 
half lives between 1.9min and 3min. During that phase (until approximately 10 min after 
injection) the plasma concentrations in all groups declined by one order of magnitude or 
more from their initial values at t = 0. Plasma concentrations in the following β-phase 
(also called elimination phase) are low and contribute only a minor fraction to the area 
under the curve (AUC). The AUC is the most relevant parameter from the viewpoint of 
drug delivery, because its value represents the concentration of a drug in the circulation, 
which is available for transport into organs (e.g., brain). Table 6 gives the AUC over the 
sampling period (0-60 min) as calculated for the different groups. Variance analysis 
revealed that the complex with bioPEGPEIODN at N/P ratio of 6:1 had a significantly 
higher AUC (by a factor of 2) compared to the other complexes (N/P = 3:1 or 10:1) and 
to free oligodeoxynucleotide. The conjugate of the 6:1 complex with the vector, 8D3SA, 
decreased its AUC.  
The results of the TCA precipitation indicated rapid degradation of the labeled NF-κB 
decoy in the circulation. By 30 min and 60 min, the precipitable fraction had decreased 
to less than 50% and 25%, respectively, in all groups. Compared to free ODN, complex 
formation with bioPEGPEI improved metabolic stability moderately, as seen for the 3:1 
and 6:1 complexes.  
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Figure 32: Comparison of AUCs (area under the plasma curve) of bioPEGPEI/NF-κB complexed 
with different amino to phosphate ratios after i.v. bolus injection into the jugular vein of a BALB/c 
mouse. On the x-axis the blood sampling times are plotted, on the y-axis the log of plasma 
concentration values is shown. 
 
 
 
 
 ODN bioPEGPEI/
ODN  
N/P=3:1 
bioPEGPEI/
ODN 
N/P=6:1 
bioPEGPEI/
ODN 
N/P=10:1 
8D3SAbioPEGPEI/
ODN 
N/P=6:1 
AUC(0 – 60min)  
[% ID . min/ml] 
185 ± 33 183 ± 11 364 ± 8* 160 ± 16 255 ± 19* 
% of control 
(NF-κB decoy) 100 99 197 86 138 
 
Table 6: Comparison of pharmacokinetic parameters of free ODN, bioPEGPEI/ODN at different 
N/P ratios and 8D3SA-bioPEGPEI/ODN at a N/P ratio of 6:1. AUC – area under the plasma 
curve; calculated by nonlinear regression fitting to a bi-exponential disposition function 
(WinNonlin).  
*significantly different with p < 0.05 
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4. Discussion 
 
All studies performed during the present dissertation are embedded in an ongoing effort 
to improve targeted DNA delivery using non-viral vectors, specifically the cationic 
polymer polyethylenimine (PEI). PEI and DNA form polyplexes, which are intensively 
studied as non-viral gene delivery vehicles, efficiently transfect plasmid DNA or 
oligodeoxynucleotides (ODNs) into a variety of cells and enable nuclear translocation of 
DNA. We used the rat anti mouse monoclonal antibody 8D3 for targeting of these 
polyplexes, to transferrin receptors. The streptavidin-biotin technology was applied for 
coupling of polyplex and vector. Synthesis and pharmacokinetic properties of 8D3-SA 
were thoroughly evaluated. A custom synthesized PEI was utilized, which carries a 
biotin-PEG moiety in a 1:1 molar ratio. The polyplexes formed with bioPEGPEI and ODN 
were intensively studied with regard to their physicochemical characteristics. The 
polyplexes had suitable size and displayed good in vitro stability under various 
conditions, including the presence of plasma. 
A brain-derived endothelial cell line (bEnd5) served as an in vitro model of the BBB, 
because the endothelial cells are the anatomical substrate of the BBB and represent the 
cellular drug target of our approach. The potential to pharmacologically modify gene 
expression at the BBB could be of considerable therapeutic interest in a multitude of 
brain diseases. Here, a phospodiester ODN decoy for the transcription factor NF-κB was 
used as drug. The decoy ODN should exert its therapeutic effects by occupying the 
binding site of activated NF-κB, thereby preventing or decreasing the transcription of 
genes with the κB response element in their promoter and inhibiting inflammatory 
reactions. EMSA for NF-κB and quantitative Northern blots for inflammatory markers 
have been established as tools for evaluating pharmacological effects on bEnd5 cells. 
Both the binding/uptake of bioPEGPEI/ODN polyplexes by bEnd5 cells and effects on 
inflammatory markers were analyzed. A complex, concentration and time dependent 
pattern of stimulation or inhibition by bioPEGPEI/ODN of the TNFα-stimulated 
expression of mRNA for VCAM-1 was seen. This shows for the first time that PEI-
mediated delivery of transcription factor decoys results in pharmacological activity. 
Notably, a good correlation was found between the increase in cellular uptake mediated 
by the 8D3-SA vector and the concentration required for inhibition of VCAM-1 gene 
expression. 
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Finally, the pharmacokinetic behavior of the free ODN and the polyplexes was studied in 
mice. Depending on the N/P ratio of the polyplexes, an up to 2-fold increase in plasma 
AUC of intact ODN was seen in comparison to ODN administered in free form.  
 
4.1. 8D3-SA as vector for drug delivery 
The pharmacokinetic results obtained with the 8D3-SA conjugate are well compatible 
with published data of vectors for drug delivery based on transferrin receptor-antibodies. 
Particularly, the mouse anti rat monoclonal anti-transferrin receptor antibody OX26 has 
been widely used in recent years (for a listing see Table 1, Introduction). The 8D3 rat 
anti mouse monoclonal antibody was generated by immunization with a brain-derived 
endothelial cell line and was subsequently characterized as specific for the TfR (Kissel et 
al., 1998). It recognizes transferrin receptors in concentrations, which were 10fold lower 
than the commercially available antibody C2F2 (Kemp et al., 1987; Kissel et al., 1998). 
Kissel et al. showed in immunocytochemical studies staining of brain parenchymal 
endothelial cells only, but not endothelial cells of fenestrated capillaries of the choroid 
plexus or the circumventricular organs. 8D3 also recognizes TfRs at the blood-testis 
barrier consisting of the Sertoli cells. In that case endothelial cells remained unstained. 
Important for its use as a vector for in vivo drug delivery is the fact that 8D3 apparently 
does not compete for Tf binding sites. This can be concluded from the absence of 
inhibitory effects on cell proliferation even at high concentrations (Kissel et al., 1998). 
It is known that rapidly proliferating cells express a high number of transferrin receptors, 
such as hepatocytes (Hirose-Kumagai et al., 1984) and erythroblasts (Morgan and 
Baker, 1988). This abundant expression was also found on endothelial cells of the BBB, 
showing that the cerebral endothelium has a key role in mediating transport of iron into 
the cell and into brain, respectively.  
The brain uptake of the MAb 8D3 was evaluated by pharmacokinetic studies in mice 
(Lee et al., 2000). In our studies we compared the recently obtained results for the brain 
uptake of the 8D3 antibody with the 8D3-SA (streptavidin) conjugate. Coupling of the 
antibody to streptavidin enables for delivery of biotinylated drugs. The avidin-biotin linker 
strategy is a well established method, leading to very tight binding because of the 
binding affinity of 1015[M-1] between streptavidin and biotin. The use of the neutral 
bacterial homolog streptavidin or neutralized avidin is favored over the native cationic 
avidin due to its extended half life in the circulation, resulting in increased AUC and brain 
uptake. Because of its charge, cationic avidin is cleared rapidly from the bloodstream by 
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the liver and kidneys with a half life of less than 1min (Pardridge et al., 1993). A neutral 
form of avidin has been published (Hiller et al., 1987; Wilchek and Bayer, 1993), which 
was obtained by removal of the carbohydrate moiety from Asn17 and neutralization of the 
residues of basic amino acids within the avidin sequence. Comparative pharmacokinetic 
experiments in rats performed with neutral avidin-OX26 antibody conjugates and the 
same conjugates with cationic avidin showed a 5-fold greater AUC for 3H-biotin/neutral 
avidin-OX26 (Kang and Pardridge, 1994). 
The 8D3 antibody demonstrated high uptake into brain tissue of up to 3.1 %ID/g (percent 
of the injected dose per g). In contrast, the OX26 antibody against the rat transferrin 
receptor, showed no brain uptake (0.06 ± 0.01 % ID/g), but behaved like a vascular 
marker in mice. Confirming the receptor-mediated character of BBB transport, saturation 
at very high doses (1 and 4mg/kg) co-administered with the tracer dose of 125I-8D3 
(approx. 15 µg/kg) could be found (Lee et al., 2000). However, for the intended use as 
drug delivery vector it is important to point out that 8D3 at a dose of 1 mg/kg still reached 
a total brain concentration of 2.46 %ID/g, corresponding to an average brain tissue 
concentration of 4.1 nM (molecular weight of 8D3 = 150kDa) (Lee et al., 2000). Coupling 
of 8D3 to streptavidin only slightly changed the pharmacokinetic behavior. The amount 
of the injected dose per gram body weight was 3.1 ± 0.4 %ID/g for the free 8D3 and 2.5 
± 0.3 %ID/g for 8D3-SA. Almost the same results were obtained for the PS products, 
showing PS values of 3.3 ± 0.1 µl/min-1g-1 for the 8D3 antibody and 2.5 ± 0.3 µl/min-1g-1 
for the 8D3-SA conjugate. The AUC and the volume of distribution remained nearly 
constant (Figure 6, Table 5). These initial in vivo experiments provided evidence that 
the 8D3-SA conjugate can be used as a brain drug transport vector. Moreover, capillary 
depletion studies performed with this vector showed binding and uptake of 33% of the 
total brain concentration of vector to the brain capillaries. One hour after bolus injection 
into BALB/c mice (Figure 7). The endothelial cell volume represents only 0.1% of the 
brain volume, i.e. 1µl/g (Farrell and Pardridge, 1991). Therefore, the local concentration 
of 8D3-SA conjugate associated with brain microvascular endothelial cells (membrane 
bound and internalized) can be estimated to be as high as 0.7µM, if an i.v. dose of 25 µg 
per mouse (1mg/kg body weight) was injected.  
To evaluate the ability of the 8D3-SA conjugate for binding/internalization in vitro, the 
endothelioma cell line bEnd5 was used and immunocytochemical and tracer binding 
studies were performed. To our knowledge no uptake studies of the 8D3 antibody on 
cultured cells were carried out previously. Immunocytochemical studies showed similar 
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staining patterns for the free 8D3 antibody and the 8D3-SA conjugate (both at a 
concentration of 10µg/ml) on bEnd5 cells and confirmed results, which were obtained on 
cryostat sections of mouse brains (Kissel et al., 1998) (Figure 8). The conjugation of 
streptavidin to this antibody did not influence its binding characteristics. In order to 
differentiate between binding and internalization of antibody conjugate we used tracer 
binding experiments in combination with a mild acid wash step to remove all surface 
associated 8D3. After a 1h incubation of 8D3-SA on bEnd5 cells a binding/uptake of 
2.7%/mg protein could be observed. Further studies showed an internalization of 3H-
biotin labeled 8D3-SA conjugate to 70% of the cell-associated activity already after 
15min of incubation (Figure 9). Increasing incubation times up to 60min did not alter the 
amount of internalized antibody, which is in good agreement with in vivo data published 
by Fishman (Fishman et al., 1987). These authors perfused rat brains with 125I-Tf and 
reported a receptor-mediated uptake of the labeled protein, rapid over the first 10-15min 
and approaching a steady-state by 60min. The specificity of uptake was confirmed in our 
studies by competing the labeled antibody conjugate with a 240fold molar excess of 8D3 
by 90%. The mouse anti-rat specific anti transferrin receptor antibody OX26 was not 
able to compete the binding.  
 
4.2. Physico-chemical characteristics of the bioPEGPEI/ODN complex 
and cell uptake 
NF-κB decoys complexed by bioPEGPEI served as our biotinylated ligand for the 8D3-
SA vector. ODNs with a natural phosphodiester backbone need to be protected against 
nucleases in plasma for in vivo application to prevent degradation. Cationic polymers, 
especially polyethylenimine (PEI), are widely used as carriers for DNA, due to their 
ability to form compact complexes (polyplexes) and transfect cells efficiently by 
adsorptive endocytosis. Polyplexes with other cationic polymers have also been studied 
intensively for gene transfer, such as polyspermine (Vinogradov et al., 1998), poly-L-
lysine (Lollo et al., 2002), polyamidoamine dendrimers (Maksimenko et al., 2003). The 
very property of these polyplexes, which enables them to undergo absorptive 
endocytosis, causes the principal problem for prospective in vivo use: nonspecific 
cellular uptake in various organs, particularly liver, spleen, kidney, and lung (Kunath et 
al., 2002; Merdan et al., 2002a). PEGylation is a modification known from protein-based 
drugs (Veronese and Harris, 2002) and the liposome field (Papahadjopoulos et al., 
1991) to improve pharmacokinetics. In the case of PEI it has been demonstrated to 
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reduce interactions with plasma proteins and blood cellular elements (Ogris et al., 1999; 
Vinogradov et al., 1999). For our purposes the linkage of biotin-PEG (MW = 3,400 Da) 
was performed at a 1:1 molar ratio with the low molecular weight (LMW) PEI (2,700 Da). 
The linear PEG chain carried a reactive N-hydroxysuccinimide ester group (NHS), which 
attached to amino groups of PEI. This introduces simultaneously the shielding PEG-
group and the coupling moiety, biotin. The synthesis used in our project is a simple one 
step procedure, taking advantage of the commercially available biotin-PEG reagent.  
We investigated the ability of bioPEGPEI to condense DNA by incubating PEI and NF-
κB decoys at different molar N/P ratios in 10mM PBS at pH 7.4 and performing 
retardation assays (Figure 11A) First, this method allowed finding of the N/P ratio where 
the complete complexation was achieved, and second, the stability of complexes under 
various incubation conditions could be tested. It should be noted that the method cannot 
provide the value of the surface charge of a certain complex, which could only be 
measured exactly by determining the ζ potential. 
bioPEGPEI/ODN complexes were formed at N/P ratios from 1:1 to 7:1, and free ODN 
served as a control. With increasing PEI/DNA ratios the fraction of DNA migrating into 
the agarose gel was reduced and was not visible at a ratio of 3:1 and above. The 
detection of ethidium bromide stained DNA in the gel pockets proved the presence of the 
complex. With increasing N/P ratios the intercalation of ethidium bromide into the DNA is 
restricted (Bieber et al., 2002), which can be observed by the lack of DNA staining in the 
pockets at ratios > 4:1. At the N/P ratio of 3:1, where complexation of DNA is just 
complete as judged from the agarose gel analysis, the interaction between cationic 
polymer and negatively charged DNA does not yet seem to be very strong, because of 
detectable free DNA, when these samples were analyzed on a 20% non-denaturating 
polyacrylamide gel (Figure 11B). However, complexes investigated at a ratio of 6:1 and 
10:1 gave identical results on either agarose or polyacrylamide gels. With respect to 
stability issues the addition of 20% human plasma to complexes at a N/P ratio of 6:1 and 
10:1 and incubation at 37°C for different time periods (0min to 120min) did not change 
the stability behavior of complexes (Figure 11C).  
A similar method was applied to test the ability of the 8D3-SA conjugate to effectively 
bind the ligand bioPEGPEI/ODN (Figure 12). The 8D3-SA conjugate was incubated with 
bioPEGPEI/ODN at different molar ratios (1/1, 1/3, 1/9, 1/27). A shift of measured 
radioactivity towards the starting point of electrophoresis compared to antibody-
conjugate migration itself revealed a binding of both components. 3H-8D3-SA peaks and 
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32P-bioPEGPEI/ODN peaks were counted and radioactivity accumulated in gel slice #7 
and #8, respectively (vs. #9 for 8D3-SA alone). Counting the 32P-activity, we observed 
that increasing molar excess of PEI (e.g. 1/27) caused an accumulation of 8D3SA-
bioPEGPEI/ODN in the slice containing the application pocket (Figure 15). This could be 
due to corresponding differences in the shielding of the cationic charge of bioPEGPEI in 
the polyplex by 8D3-SA. Shielding of surface charges of polyplexes by protein 
(transferrin) has been described by Kircheis et al. (Kircheis et al., 2001b). 
Cell binding and uptake studies were carried out with the brain endothelial cell line 
bEnd5. The uptake of free ODN, bioPEGPEIODN and 8D3SA-bioPEGPEIODN at an 
antibody to bioPEGPEI ratio of 1:1 was compared (Figure 16). The incubation of free 
ODN on bEnd5 was used as a negative control. Our tracer uptake studies showed an 
uptake of only 0.2% of free ODN after 60min of incubation. Due to their phosphate 
groups oligodeoxynucleotides have a strong negative charge and repelling interaction 
with the negatively charged cell membrane prevents their uptake into the cell. The 
positively charged PEI showed higher internalization and increased cellular 
accumulation in cells due to adsorptive-mediated endocytosis (Ogris et al., 2001). 
Shielding of PEI with PEG masks the surface charge of the polymer and reduces the 
non-specific binding to cell membranes (Kircheis et al., 2001a). We observed 
internalization of complex without 8D3-SA of up to 2%, most likely due to absorptive 
mediated endocytosis. A 3-fold increase in uptake was achieved by targeting the 
transferrin receptors on these bEnd5. The overall increase in cellular uptake mediated 
by the vector and bioPEGPEI compared to free ODN is therefore more than 50-fold after 
60 min. For comparison, the group of Kabanov measured in vitro uptake of transferrin-
targeted PEGPEI/ODN by various carcinoma cells and reported an 80-fold enhancement 
after 6h in the uptake of fluorescent labeled phosphorothioate antisense ODN compared 
to PEGPEI/ODN complexes without transferrin (Vinogradov et al., 1999). 
We extended our uptake experiments with a fluorescence microscopy study on bEnd5 
cells, which revealed no uptake of free ODN (0.5µM or 2µM) during time periods up to 
8h. In contrast, uptake of bioPEGPEI/ODN complexes was readily detected. The cells 
displayed a staining of the plasma membranes after 30min and clearly visible staining of 
the nuclei after 8h of incubation, suggesting an endosomal escape of DNA or complexed 
DNA, respectively (Figure 17). Our results with the doublestranded ODN decoy fit well 
with studies in which plasmid DNA or synthetic ribozymes were used. Pollard and 
colleagues (Pollard et al., 1998) investigated the transport of naked and PEI-complexed 
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plasmid DNA into the nucleus. They reported a hardly detectable nuclear uptake of 
naked DNA compared to PEI associated DNA after direct injection into the cytoplasm of 
various mammalian cell lines. Recently Bieber et al. (2002) showed colocalization of 
plasmid DNA complexed with PEI in perinuclear granular structures at 3-5h after 
transfection of cells using confocal laser scanning microscopy. Merdan et al. (2002b) 
used confocal laser scanning microscopy on living cells to demonstrate endosomal 
release and nuclear uptake of a fluorescently labeled ribozyme, which was also 
delivered to cells as a PEI complex. 
The physico-chemical characterization of bioPEGPEI/ODN polyplexes was expanded by 
size measurements at different N/P ratios using dynamic light scattering. The size of a 
cationic complex strongly depends on the N/P ratio, and modification of polymer and 
buffer, in which the complex was formed. Complex formation was carried out in 10mM 
PBS at pH 7.4 at N/P ratios from 3:1 to 60:1 (Figure 17). Notably, there were no major 
changes in size observed over the range of N/P ratios. At a ratio of 3:1 complex sizes 
started at about 130nm and remained stable over a time period of at least one week. 
Complexes slightly smaller (about 120nm) were observed at a ratio of 6:1 with a 
narrower Gaussian distribution than obtained for 3:1 complexes. These results suggest a 
tighter condensation between DNA and PEI at a ratio of 6:1. Even for 60:1 complexes 
complex sizes were estimated at 160-200nm. The reason for the stability in complex 
sizes may be that the effect of the PEG moiety offsets the increasing N/P ratio, which 
would otherwise cause complexes to be more compact. Ogris and colleagues reported 
that there is a tendency for aggregation of non-modified complexes at low N/P ratios 
near electroneutrality. This aggregation can be prevented by increasing of N/P ratio > 
6:1 or higher (Ogris et al., 1998). PEGylation has also been shown to have an influence 
on aggregation characteristics of PEI. PEG exerts its effects by its nonionic water-
soluble chains (Vinogradov et al., 1998). The stabilizing effect of PEG was confirmed in 
our studies, even at low N/P ratios we observed constant size measurements over 
extended time periods.  
The coupling of the 8D3-SA conjugate to bioPEGPEI/NF-κB at a molar 
8D3SA/bioPEGPEI ratio of 1:1 increased the particle size by about 40nm to 160nm 
(Figure 19), which was stable for at least 24h. The same experiments carried out in 
complete DMEM medium without FCS showed a size of 160nm for bioPEGPEI/ODN 
complexes after 10min of incubation, increasing over time to 280nm after one week due 
to additional salt binding to the complex (Figure 20). Size measurements in the 
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presence of serum or plasma proteins would be desirable, however these are 
notoriously difficult with dynamic light scattering. The presence of lipoprotein particles 
and macromolecules interferes with the signal and requires multimodal size analysis, 
which is prone to artifacts. 
A combination of stability tests, consisting of ultrafiltration and TCA precipitation, was 
used to investigate the behavior of bioPEGPEI/DNA complexes after incubation in 10mM 
PBS at pH 7.4 or in cell culture medium (DMEM+ with 10% FCS) for periods up to 24h at 
37°C (Figure 21). The complex was TCA precipitable to nearly 100% (in PBS) and 88% 
(in DMEM+ with 10% FCS) directly after labeling, proving the initial integrity of 
bioPEGPEI/ODN. When PBS was used as the incubation medium, 100% of free ODN 
passed through the filtration membrane, as opposed to complete retention of 
bioPEGPEI/ODN. In the case of DMEM+ with 10% FCS as the incubation medium for 
free ODN, still 70% passed through the membrane, suggesting only minor plasma 
protein binding. A 24h incubation in either PBS or DMEM+ with FCS did not increase the 
filterable fraction to more than 3.4%, and the stability was confirmed by TCA 
precipitation studies. Interestingly, results obtained for incubation of bioPEGPEI/DNA 
complex on bEnd5 cells for the same periods showed a different picture (Figure 22). 
The filterable 32P radioactivity after 24h incubation of complexes on cells was almost the 
same as the filterable fraction of free ODN in medium with serum. This clearly indicates 
a gradual decay of the complexes in the presence of cells. Moreover, the low TCA 
precipitability of 34% after 24h also shows susceptibility to metabolic degradation. A 
potential explanation of this behavior could be the observation that cationic polyplexes 
interact with negatively charged cell surface proteoglycans (Mislick and Baldeschwieler, 
1996), and the interaction could disrupt the complexes over time.  
 
4.3. NF-κB gel shift assays for analysis of activation pattern after 
stimulation with LPS/TNFα or LPS 
The starting point of our investigations on the induction of an inflammatory response in 
vitro was the activation of the transcription factor NF-κB by TNFα and LPS. Signals 
generated by ligand receptor interactions at the plasma membrane ultimately cause an 
alteration of gene expression of effector molecules, such as cytokines and adhesion 
molecules (Ghosh and Karin, 2002; Ghosh et al., 1998). In its resting state, NF-κB is 
associated with its inhibitory component IκB in cytoplasm. After receptor activation, an 
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IκB kinase (IKK) complex is responsible for phosphorylation of IκB. IκB is then 
specifically ubiquitinated, dissociates from NF- κB and is digested by the proteasome. 
The free dimeric NF-κB translocates into the nucleus.  
In recent years efforts have been made to inhibit the NF-κB pathway at different levels of 
activation. Specific inhibition of NF-κB was initially explored in studies with IκBα mutants 
(Baldwin, 1996; Ghosh et al., 1998) lacking the ability for phosphorylation and 
degradation by the proteasome. However, a therapeutic use would require the 
transfection of cells with genes coding for dominant negative IκB mutants (Yamamoto 
and Gaynor, 2001).  
Alternatively, the transcription factor decoy approach could be a viable strategy for 
clinical use (Dzau, 2002). ODN decoys for NF-κB have recently been evaluated in 
human brain derived endothelial cell culture by Hess et al. (2000) with the goal to inhibit 
inflammatory reactions associated with brain ischemia/reperfusion. The murine brain 
derived bEnd5 cells, which we chose, have been previously utilitized for lymphocyte 
transmigration assays, and their expression of adhesion molecules has been measured 
(Laschinger and Engelhardt, 2000). Because the activation pattern of NF-κB has not 
been studied before in bEnd5, we wanted to demonstrate first its stimulation in nuclear 
extracts using EMSA.  
We could show that NF-κB was constitutively active at low levels under control 
conditions, and that the signals increased strongly after 1min and 5min of TNFα/LPS 
stimulation. A second peak of activity appeared after 60min to 120min (Figure 23). 
Similar time courses of NF-κB activation have been reported in another tissue (pancreas 
acini) (Gukovsky et al. 1998) and in different cell lines (Hoffmann et al., 2002) and were 
attributed to a differential degradation of IκBα and IκBβ. The inflammatory stimuli used 
here, were in the range commonly applied, for example the LPS concentrations of 
1µg/ml for stimulation correspond to a study with HUVEC by Madan et al. (2000). 
Similarly, TNFα concentrations of 50ng/ml were in the range of 10-100ng/ml as used by 
others (Botella et al., 2000; Madan et al., 2000). 
NF-κB gel shift assays after LPS stimulation alone showed a different, monophasic 
stimulation pattern, with increasing activity after 5min and peak activity after 10min, and 
a gradual decline from 30 to 120min (Figure 24).  
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4.4. mRNA expression of inflammatory markers after LPS, TNFα, and 
LPS/TNFα stimulation 
The gene expressions of IκBα and IκBβ, of adhesion molecules, such as VCAM-1 and 
ICAM-1, and of enzymes involved in inflammatory reactions (COX-2, iNOS) gives us a 
read-out suitable for quantitative evaluation of pharmacological effects at the cellular 
level. Therefore, the time course of mRNA expression for these markers after defined 
stimuli (LPS, TNFα, and a combination of LPS/TNFα) was established. bEnd5 cells were 
treated over a time frame of 360min and the extent and the profile of up-regulation of 
markers was compared.  
Due to its role as a negative feedback regulator, measurements of IκBα at the mRNA or 
protein level can be used as surrogate markers of activity of the NF-κB system. This has 
also been applied to brain microvessel endothelial cells in situ (Quan et al., 1997; 
Laflamme  and Rivest, 1999). In our Northern blots (Figures 25-27) we could see robust 
stimulation of IκBα expression. TNFα and the combination TNFα/LPS stimulated the 
message earlier (by 30 min) and stronger than LPS alone. Interestingly, the mRNA of 
IκBβ was also significantly increased at later time points (120min and later) under TNFα 
and TNFα/LPS treatment, but not under LPS alone. Because the promoter for IκBβ lacks 
a κB element, it is generally assumed that IκBβ is not subject to regulation by NF-κB 
(Hoffmann et al., 2002). The pattern of upregulation of both isoforms, IκBα and IκBβ, in 
bEnd5 cells has recently been fully confirmed in our lab by real time RT-PCR 
measurements of these messages. However, a confirmation at the protein level will also 
be required (Western blots of cytosolic and nuclear extracts), and these studies are 
currently in progress.  
In MS the recruitment of autoaggressive T lymphocytes from the blood across the BBB 
is mediated through interactions of adhesion molecules (ICAM-1, VCAM-1) on the 
endothelial cells and their counterparts LFA-1 and VLA-4, respectively, on lymphocytes. 
After passing the endothelial barrier T-lymphocytes may encounter CNS myelin 
antigens, which results in stimulation of helper T lymphocytes, lymphocyte proliferation, 
macrophage activation, and cytokine secretion.  
We found on our bEnd5 cells under control conditions that ICAM-1 mRNA is present at 
low levels, which is in good agreement with published data (Dietrich, 2002; van de 
Stolpe and van der Saag, 1996). At the concentrations we used, TNFα (50ng/ml) was a 
strong and LPS (1µg/ml) was a moderate inducer of ICAM-1. mRNA levels rose 
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continuously over the covered period of 6h for TNFα, but  peaked at 120min under 
stimulation with LPS. A combination of LPS/TNFα stimulation neither increased the 
levels obtained after TNFα activation alone, nor changed the stimulation profile, 
suggesting a predominant role of TNFα in mediating the up-regulation of ICAM-1 under 
the conditions used here. The same pattern can be reported for the VCAM-1 mRNA.  
The increased gene expression observed for iNOS (after LPS and/or TNFα) and COX-2 
(after TNFα and LPS/TNFα) corresponded with the data published on neuroinflammtory 
conditions. In EAE models, mRNA levels for iNOS in brain rise after induction of the 
disease. It could be shown that the induction of iNOS mRNA coincided with the severity 
of clinical signs, and in some cases with the presence of inflammatory cells in the brain 
(Koprowski et al., 1993). Confirming a function of iNOS in the disease process, an 
amelioration of EAE with a selective inhibitor of the inducible nitric oxide synthase 
(iNOS) could be achieved (Hooper et al., 1997). Previous studies have also indicated 
that the prostaglandin producing COX-2 is increased in cerebral endothelial cells of 
EAE-affected rats, which was closely linked to disease progression (Deininger and 
Schluesener, 1999).  
  
4.5. Effect of NF-κB decoy on the expression of VCAM-1 
The treatment of bEnd5 cells with the bioPEGPEI/ODN drug (Figures 28-31) can be 
summarized as follows: (a) VCAM-1 mRNA (isoform1 and 2) is downregulated in a time 
dependent manner by treatment of cells for 4h to 48h before stimulation with TNFα for 
4h. (b) The treatment effect was seen in the presence or absence of serum. (c) the 
polyplex itself (without subsequent TNFα stimulation) did not stimulate VCAM-1 gene 
expression. (d) A clear dose-response relation over the concentration range 0.1µM to 
5µM was observed. (e) The vector, 8D3-SA, enhanced the potency by about an order of 
magnitude (0.5 µM with 8D3-SA was more effective than 5 µM without vector). 
These results show for the first time that a phosphodiester ODN decoy delivered by 
modified PEI has specific pharmacological activity at submicromolar concentrations. 
Obviously the ODN-drug is able to reach the effect compartment inside the cell (cytosol 
and/or nucleus) where it can bind to activated NF-κB. Previously, effects with ODN-
based drugs after delivery with PEI have only been shown for a phosphorothioate 
antisense ODN (Vinogradov et al., 1999), and recently for a ribozyme (Aigner et al., 
2002). In the first case an antisense ODN to mdr-1 was delivered to human epidermoid 
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carcinoma cells, and a suppression of p-glycoprotein was seen after 48h of treatment at 
0.5µM. The delivery system was based on a biotinylated PEG-PEI coupled to 
biotinylated transferrin as targeting vector via an avidin bridge. In the second case, an 
unmodified ribozyme against fibroblast growth factor binding protein (FGF-BP) was 
delivered with low molecular weight PEI to carcinoma cells in vitro and to tumor 
xenografts in vivo. The ribozyme was active at low concentrations in vitro (0.1-1 µg/mL) 
and in vivo (0.4 mg/kg), but only in complex with PEI, not in free form.  
The inhibitory effect on stimulated expression of mRNA for VCAM-1 as observed in the 
present study is comparable to the effect of interferon-β as recently described by Floris 
and colleagues (Floris et al., 2002). These authors also utilized brain-derived endothelial 
cell cultures. Interferon β is the most potent drug currently available for therapy of MS.  
Our present results provide preliminary evidence that the proposed hypothesis for a new 
treatment strategy in neuroinflammatory disease may hold true. Obviously, further 
detailed studies into the cellular mechanism of action are required. For example, the 
stimulatory effect on VCAM-1 mRNA seen at low concentrations remains currently 
unexplained, and the potential of cellular toxicity needs to be investigated over a wider 
range of concentrations and incubation times. Also, controls of the specifity of the 
pharmacological activity need to be performed by the use of different, unrelated ODNs 
(or scrambled sequences) and by analysis of different parameters (e.g. ICAM-1, iNOS, 
IκBα). 
 
4.6. Pharmacokinetic characteristics of bioPEGPEI/NF-κB 
The interpretation of the results of the pharmacokinetic study can be based on the 
underlying hypothesis: The complexation of ODN by PEI should prevent the degradation 
of DNA in the circulation. Moreover, shielding of the DNA/polymer complex with PEG 
should further improve stability and lead to an increase of the AUC in plasma, equivalent 
to a decrease in systemic clearance. Here, the effect on oligodeoxynucleotide stability 
was found to be significant with an increase of AUC by 98% (N/P = 6:1 complex vs. free 
ODN). Recently, collaborators reported a 62% increase in AUC for PEGylated 
copolymers with 25kDa PEI (Kunath et al., 2002). However, a direct comparison is not 
possible, because PEI was radiolabeled in the cited work, and the pharmacokinetic of 
free ODN could not be measured. Characterizing the elimination of the ODN moiety, as 
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performed here, may be more relevant with regard to the intended use of these 
polymer/ODN complexes as drug delivery vehicles for DNA-based drugs.  
Despite similar complex sizes in physiological buffer (Figure 17), physicochemical 
differences may be responsible for the lower AUCs observed for the 3:1 and 10:1 
complexes compared to the 6:1 complexes. Complexes formed at N/P= 3:1 are just able 
to completely bind DNA (Figure 15) and would be expected to have limited stability in 
high salt solutions. Complexes at N/P =10:1 have a larger excess of cationic charge 
compared to the 6:1 complexes, which may be insufficiently shielded by the PEG tails. 
More cationic particles will interact more strongly with the anionic cell surfaces and 
would be cleared from the circulation faster. 
While there was a significant change in the plasma AUC for the 6:1 complexes versus 
free ODN, the protection from metabolic breakdown of ODN was limited. The TCA 
precipitable fractions (Figure 31) show that most of the ODN in plasma was degraded 
within 10-20min. This behavior could not be predicted from the in vitro studies. As shown 
in Figure 21, the labeled NF-κB decoy was stable when incubated in cell culture media 
with plasma addition, and it was fully protected from degradation for at least 1 hour in the 
presence of endothelial cells. On the other hand, the present in vivo results correspond 
well to recent in vivo data with dual labeled complexes of PEGylated PEI (MW=25kDa) 
and ODN (unpublished data from our laboratory). 
Although organs had been sampled from the animals at the end of the 60 min period, 
evaluations of individual organ uptake were not performed. The fact that the major 
fraction of plasma radioactivity must be attributed to low molecular weight metabolites 
(free nucleotides, water) indicated that evaluation of total tissue radioactivity would be 
meaningless. Detailed analysis of tissue associated radioactivity using DNA extraction 
and PAGE, will be pweformed in future studies. Modifications of the PEGPEI co-polymer 
may be required to achieve further improvements in the pharmacokinetic behavior of the 
polyplexes.   
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5. Summary 
 
In this project a vector for drug delivery into brain endothelial cells, consisting of an anti-
transferrin receptor antibody and a complex of polyethylenimine (PEI) and an 
oligodeoxynucleotide (ODN) drug was evaluated. NF-κB decoys are short double-
stranded ODNs, which contain a recognition sequence for binding to the transcription 
factor. By binding to the transcription factor NF-κB they prevent the transcription of 
several genes involved in inflammatory processes, such as adhesion molecules and pro-
inflammatory enzymes. Adhesion molecules promote the transmigration of activated T 
lymphocytes across the blood-brain barrier (BBB), leading to demyelination of nerve 
fibers within the brain, as seen in inflammatory diseases like Multiple Sclerosis (MS). 
Inhibition of lymphocyte transmigration by downregulation of the expression of these 
genes may be therapeutically beneficial. 
The rat anti mouse anti-transferrin receptor antibody 8D3 was purified from hybridoma 
supernatant and was conjugated to recombinant streptavidin (SA) in order to bind to 
biotinylated ligands. In vivo pharmacokinetics and in vitro binding studies were 
performed to evaluate the 8D3-SA vector. Pharmacokinetic studies showed a 
comparable half-life and area under the curve (AUC) of antibody conjugate and free 8D3 
antibody in plasma. Immunohistochemistry with a brain endothelioma cell line (bEnd5) 
revealed a similar binding behavior for both, antibody and its streptavidin conjugate. The 
specificity of uptake of 3H-biotin-8D3SA by bEnd5 cells could be observed in 
experiments carried out either with an acid wash step to remove all surface bound 
antibody, or by using the mouse anti rat transferrin receptor antibody OX26.  
The biotinylated drug applied in this project was a polymer – polyethylenimine (PEI), 
which is able to complex a double-stranded 20bp ODN sequence (NF-κB decoy). The 
low molecular weight PEI (LMW PEI) of 2,700 Da was chosen due to such favorable 
properties as low cytotoxicity, high transfection efficiency, and narrow size distribution. A 
co-polymer of PEI and biotinylated PEG was synthesized to allow coupling to the vector. 
Stability studies were carried out to examine the characteristics of bioPEGPEI/ODN 
complexes in salt solution, under addition of 10% or 20% plasma, or by incubation of 
complex in medium over a long time frame. Particle size measurements in PBS pH 7.4 
revealed an optimal size distribution of bioPEGPEI/NF-κB complex at a ratio PEI-
amine/ODN-phosphate of 6:1 with an average particle size of 120nm, which was stable 
for at least 1 week. Gel retardation assays also showed a complete complexation of 
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bioPEGPEI and ODN at this ratio. The addition of 8D3-SA increased the complex size 
by 40nm. 
In vitro pharmacological effects of bioPEGPEI/NF-κB could be observed after treatment 
of bEnd5 cells with different concentrations of NF-κB decoy over a time frame of 48 
hours. An inhibition of VCAM-1 (isoform 1 and 2) expression was already visible after 12 
hours with a steady increase of this inhibitory effect to 48 hours. ODN-drug 
concentrations of 5µM in complex with bioPEGPEI showed a nearly complete 
suppression of VCAM-1 expression. Coupling of bioPEGPEI/NF-κB decoy to the vector 
decreased the concentration required for a reduction of VCAM-1 mRNA to 0.5µM - 1µM, 
suggesting an increase in potency by targeting to the transferring receptor.  
Pharmacokinetic studies in mice showed the behavior of bioPEGPEI/NF-κB complexes 
with different N/P ratios. At a N/P ratio of 6:1 the AUC (area under the plasma curve) 
could be increased 2-fold compared to free NF-κB. A coupling to the targeting vector did 
not further change the pharmacokinetic characteristics. 
The drug targeting approach investigated in this project promises to be an excellent 
model for in vitro applications. The in vivo administration must be further evaluated with 
the goal to improve the pharmacokinetic behavior (enhance AUC). This may require 
additional modifications of the bioPEGPEI copolymer. 
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6. Zusammenfassung 
 
In diesem Projekt sollte ein Vektor zur “Drug delivery” an Hirnendothelzellen, bestehend 
aus einem monoklonalen Antikörper gegen den Transferrinrezeptor und einem Komplex 
aus Polyethylenimin (PEI) / Oligodeoxynukleotid (ODN) untersucht werden. NF-κB 
“decoys” sind kurze doppelsträngige Oligodeoxynukleotide, welche eine 
Erkennungssequenz für die Bindung des Transkriptionsfaktors enthalten. Durch die 
Bindung an den Transkriptionsfaktor NF-κB verhindern sie die Transkription von 
verschiedenen, in entzündliche Prozesse involvierte Genen. Adhäsionsmoleküle fördern 
die Transmigration von aktivierten T-Lymphozyten über die Blut-Hirn-Schranke (BHS), 
die zu Entzündung und zu einer Demyelinisierung von Axonen im Gehirn führt. Dieser 
Zustand wurde in entzündlichen Erkrankungen wie der Multiplen Sklerose (MS) 
gesehen. Die Hemmung der Transkription dieser Gene kann durch verminderte 
Lymphozytentransmigration zu therapeutischen Effekten führen.  
Der Ratte-anti-Maus-Antikörper 8D3 gegen den Transferrinrezeptor wurde aus 
Hybridommedium gereinigt und an Streptavidin gekoppelt, um biotinylierte Liganden 
binden zu können. Zur Vektoranalyse wurden in vivo Pharmakokinetikstudien und in 
vitro Bindungsstudien durchgeführt. Die Pharmakokinetikstudien zeigten eine 
vergleichbare Halbwertszeit und Fläche unter der Plasmakurve (Area under the plasma 
curve = AUC) des Antikörperkonjugates und freien 8D3 Antikörpers im Plasma. 
Immunhistochemie an der Hirnendothelzelllinie bEnd5 zeigte ein ähnliches 
Bindungsverhalten für den Antikörper und das Streptavidinkonjugat. Die Spezifität der 
Aufnahme von 3H-Biotin-8D3-SA durch die bEnd5 Zellen wurde in Experimenten 
bestätigt, die entweder mit einem Säurewaschschritt zur Entfernung aller 
oberflächengebundenen Antikörper oder durch Anwendung des Maus-anti Ratte-
Transferrinrezeptor-Antikörpers OX26 durchgeführt wurden.  
Der biotinylierte Ligand, der in diesem Projekt verwendet wurde, war ein Polymer – 
Polyethylenimin (PEI), das in der Lage ist, eine doppelsträngige 20 Basenpaare lange 
Sequenz (NF-κB “decoy”) zu komplexieren. Das PEI mit niedrigem Molekulargewicht 
(low molecular weight = LMW PEI) mit 2700Da wurde für dieses Projekt gewählt, weil es 
durch solche positiven Eigenschaften wie geringe Zytotoxizität, hohe Transfektionsraten 
und enge Größenverteilung bekannt ist. PEI wurde kovalent mit einem biotinylierten 
PEG modifiziert, um die Kopplung an den Vector zu ermöglichen. 
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Wir führten Stabilitätsstudien zur Analyse der Komplexeigenschaften in Salzlösungen 
unter Zusatz von 10% oder 20% Plasma und Inkubation des Komplexes in Medium über 
einen längeren Zeitraum durch. Partikelgrößenmessungen in PBS mit einem pH-Wert 
von 7.4 zeigten eine optimale Größenverteilung des bioPEGPEI/NF-κB-decoy 
Komplexes mit einem PEI-Amino/ODN-Phosphat (N/P) Verhältnis von 6:1 und eine 
durchschnittliche Partikelgröße von 120nm, welche für mindestens eine Woche stabil 
war. Gelretardationsassays zeigten bei diesem N/P-Verhältnis ebenfalls eine 
vollständige Komplexierung von PEI und ODN. Die Zugabe des 8D3-SA erhöhte die 
Komplexgröße um 40nm. 
Pharmakologische Effekte von bioPEGPEI/NF-κB decoy in vitro konnten nach der 
Behandlung der bEnd5 Zellen mit verschiedenen Konzentrationen der NF-κB “decoys” 
über einen Zeitrahmen von 48 Stunden beobachtet werden. Eine Hemmung der mRNA 
für VCAM-1 (Isoform1 und 2) war bereits nach 12 Stunden sichtba,r mit einem stetigen 
Anstieg des inhibitorischen Effektes bis zu 48 Stunden. Die Pharmakonkonzentrationen 
von 5µM zeigten eine nahezu vollständige Supprimierung der VCAM-1-Expression. 
Kopplung des Pharmakons an den Vektor führte zu einer Reduktion der Konzentration 
auf 0,5µM - 1µM, die zur Hemmung der Genexpression benötigt wird. Diese Ergebnisse 
sprechen für eine Erhöhung der Potenz des Pharmakon-Komplexes durch “targeting” an 
den Transferrinrezeptor. 
Pharmakokinetikstudien zeigten das Verhalten des bioPEGPEI/NF-κB-Komplexes mit 
verschiedenen N/P Verhältnissen. Bei einem N/P Verhältnis von 6:1 konnte die AUC im 
Vergleich zu freiem NF-κB verdoppelt werden. Die Kopplung an den Vektor veränderte 
die pharmakokinetischen Eigenschaften des Komplexes nicht wesentlich. 
Die “drug targeting” Methode, die in diesem Projekt untersucht wurde, stellt ein 
exzellentes Modell für in vitro Anwendungen dar. Weitere Untersuchungen zur  in vivo 
Anwendung sind notwendig, mit dem Ziel einer weiteren Verbesserung der 
pharmakokinetischen Parameter (Erhöhung der AUC). Hierzu können weitere 
Modifikationen des bioPEGPEI erforderlich sein. 
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